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Abstract
Development of Small Molecule Neuroprotectants
By Ashley G. Boice, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2018.
Major Director: Shijun Zhang Associate Professor, Department of Medicinal Chemistry

Neurodegenerative diseases are a class of conditions that lead to progressive
atrophy of different parts of the central nervous system (CNS). These diseases lead to
devastating clinical outcomes to patients and give rise to an enormous socio-economical
burden on society.1 One commonality among some of the most well-known
neurodegenerative disorders, e.g. Alzheimer’s disease (AD), Parkinson’s disease (PD),
and multiple sclerosis (MS), is neuroinflammation.2-4 Neuroinflammation stems from
interactions of the innate immune system with toxins and insults to the central nervous
system. In the case of irremovable or chronic insults and toxins, this leads to chronic
damaging inflammation that hastens neuronal degeneration and exacerbates disease
pathology.5,6 Recently, inflammasomes of the innate immune system have been indicated
in playing essential roles in the observed inflammatory responses. The most studied
inflammasome is the nod-like receptor pyrin containing 3 (NLRP3) inflammasome. 7–9
Recently our research group has successfully developed sulfonamide-based small
molecule inhibitors of the NLRP3 inflammasome, such as JC-21 and JC-171, as potential
xix

therapeutics for AD and MS. Our studies established that JC-21 is a selective inhibitor of
the NLRP3 inflammasome.10,11 Structural modifications led to the development of JC-171
with improved pharmacokinetic properties. More importantly, our studies demonstrated
the in vivo activity of JC-171 to effectively ameliorate the experimental autoimmune
encephalomyelitis (EAE), a mouse model of MS.12 Our data also strongly suggested that
inhibitors based on this

chemical scaffold may directly target

the

NLRP3

inflammasome.10–12 In this dissertation, we conducted biophysical, biochemical, and
modeling studies to further elucidate the mechanistic information of these compounds as
inhibitors of the NLRP3 inflammasome. In order to conduct further mechanistic studies,
the NLRP3 protein was produced via transfection of HEK 293 cells with a modified
plasmid of full-length human NLRP3 protein.13 Furthermore, LC-MS studies were
conducted to confirm the blood-brain barrier penetration (BBB) of JC-171. Our studies
established that JC-171 directly binds to the NLRP3 protein. The results also suggested
that JC-171 may bind to the NACHT domain of NLRP3 while in a site that is distinct from
the ATP binding site. This notion is supported by the fact that our compounds do not
interfere with the ATPase activity of NLRP3. Docking studies of JC-171 to the homology
model of the NACHT domain of NLRP3 also supported this assertion by showing the
interaction of JC-171 with residues that are not overlapping with the ATP binding pocket.
BBB penetration studies in combination with LC-MS analysis confirmed that JC-171
shows better BBB penetration when compared to MCC950. Collectively, our results
strongly support that our compounds function as NLRP3 inflammasome inhibitors by
directly binding to the NLRP3 protein, a novel and distinct mechanism of action when
compared to the known inhibitors that target the NLRP3 inflammasome pathway. These

xx

results strongly encourage further development of such inhibitors as potential
therapeutics for neurodegenerative diseases.

xxi

Chapter 1: Introduction
Neurodegenerative diseases are a class of conditions that lead to progressive
atrophy of different parts of the nervous system. These diseases can lead to a broad
range of symptoms presented, from motor dysfunction in Parkinson’s disease (PD) to the
significant cognitive decline seen in Alzheimer’s disease (AD). Various genetic mutations,
toxins, insults, and autoimmune responses have been known to cause these ailments
and the incidence of such diseases often increases with age. In addition to the detrimental
effects to the health and well-being of the affected individuals, neurodegenerative
diseases have become a growing concern as the healthcare costs are increasing as the
senior population increases in numbers.

14,15

The most well-known neurodegenerative

diseases are AD, PD, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). 16
AD, the most common type of dementia, is estimated to affect more than 5 million
Americans of all ages in 2017 and up to 36 million individuals worldwide currently. It is
predicted that more than 88 million Americans will have AD by 2050.17 AD will cost
Americans an estimated 277 billion dollars for the year 2018. 18 The estimated occurrence
of PD, the second most common neurodegenerative disease, in 2010 was approximately
630,000 in the United states and is projected to double by 2040. Additionally, PD cost
Americans more than 14.4 billion dollars in 2010.19 Finally, MS affects an estimated
400,000 Americans and the least common but well known, ALS, affects an estimated
30,000.20,21 Each neurodegenerative disease has its own distinct and comparably
devastating clinical manifestations but based on the data presented the disease with the
greatest socioeconomical burden is AD.
1

1.1 Alzheimer’s Disease
1.1.1 AD History and Disease Presentation
AD was discovered by Dr. Alois Alzheimer who examined a patient of Frankfurt
Asylum who died of an undocumented mental illness characterized by memory loss,
paranoia, and personality changes. In his examination, Dr. Alzheimer identified atrophy
of the cerebral cortex and the abnormal histopathology including the deposits of neritic
plaques and neurofibrillary tangles.22 Since then, the scientific community has made
further progress in characterizing AD. AD is the most common form of dementia and
accounts for 60 to 80% of all dementia cases.17 In early stages of the disease, the
cognitive symptoms are milder and consist of episodic memory loss, taking longer to finish
tasks, and increased anxiety. In moderate AD, the symptoms become more impactful and
can include retrograde memory loss, paranoia, personality changes, difficulty with simple
tasks, and getting lost. In severe AD, patients can lose the ability to communicate, have
difficulty swallowing, and loss of bladder and bowel control.17,23
There are two types of AD, early-onset AD (EOAD) and late-onset AD (LOAD). Of
all AD diagnoses, 10% are diagnosed with EOAD. Patients with EOAD begin to present
with symptoms from as young as age 30 to 65. The main difference in the disease
presentation of EOAD and LOAD is the increased frequency of symptoms aside from
memory impairment in EOAD, such as visual dysfunction, language impairment, and
difficulty executing purposeful movements.24 The cause of these symptoms in EOAD is
mutations to genes for either amyloid precursor protein (APP), presenilin-1 (PSEN1), or
presenilin-2 (PSEN-2). A variant of apolipopotein E, apolipoprotein ε4, is also known to

2

increase susceptibility to the disease for LOAD or EOAD.
However, the cause of LOAD is largely unknown but might be a combination of
genetic risks and environmental factors.1,25 Some of these potential risk factors that have
been investigated include air pollution,26 insecticide DDT,27 head injury,28 chronic
inflammation, 29 and type 2 diabetes mellitus.30 Despite its prevalence and unclear cause,
LOAD is not considered to be a part of the normal aging process. This being apparent
from the similarities in both pathology and clinical presentation to EOAD.31 The
devastating emotional, physical, and socioeconomical impact of AD has sparked an
enormous effort of the scientific community to find an effective therapeutic treatment or
cure for this disease. Without one certain cause in this multifactorial disease, multiple
targets

have

been

investigated

based on the known histopathology.
1.1.2 AD Histopathology
The known histopathological
changes in AD include toxic amyloidβ (1-42) (Aβ42) oligomers and the
fibrillar form of amyloid-β, which
deposits of lead to the formation of
neritic plaques.
disease

is

Additionally, the
characterized

by

anomalously phosphorylated tau
that forms filaments and lead to the

Figure 1. The histopathology of AD in the brain
compared with healthy brain. Adapted from Jin.34

buildup of neurofibrillary tangles.
3

With chronic sources of inflammation, glial scar formation from failed attempts correct
these insults, and synaptic loss,32 in time, neurons fail to function properly or interact and
eventually can lead to neuronal death. Neuronal death in AD frequently occurs with
cholinergic neurons in the hippocampus and neocortex of the brain.33 With the increasing
loss of dendrites, axons, and neurons, the brain shrinks.34,35 This atrophy of the brain
becomes apparent as the cortex and hippocampus visibly shrink and the ventricles fill
with fluid (Figure 1).34 To better understand these toxic insults that trigger the
degeneration in the AD brain, further details on the two hallmarks, amyloid-β and tau,
need to be discussed.
1.1.3 Aβ hypothesis
The first hypothesis to explain the pathology in AD, the amyloid cascade
hypothesis (ACH), argues that amyloid-β peptide deposition in the brain is the triggering
event leading to the pathology of AD. The major supporting evidence of this hypothesis
is EOAD. Mutations to amyloid precursor protein (APP) and part of its gamma-secretase
complex,

presenilin,

lead

to

AD

pathology, directly connecting amyloid-β
to AD.36 A key player in the hypothesis
is APP, APP is a transmembrane protein
with the larger N-terminal on the
extracellular side of the membrane and
the
Figure 2. The processing of APP. Adapted
from Kaether and Haass.37

smaller

C-terminal

on

the

intracellular side. From knock-out and
mutation studies, the function of the
4

protein appears to be the maintenance of synapses and regulation of signaling the growth
of dendrites and axons. APP can be cleaved by alpha-secretase to produce sAPP-alpha
and C83. When cleaved by beta-site APP-cleaving enzyme 1 (BACE-1) it can produce
sAPP-β and C99. C83 and C99 can then be further cleaved by gamma-secretase to
produce P3 or amyloid-β, respectively, (Figure 2).37 The amyloidogenic pathway,
following cleavage of C99 can produce amyloid-β at varying sizes but more frequently
amyloid-β-40.38,39
Aβ42 is one of the most dangerous fragments because of its ability to form fibrils
and oligomerize.40 The levels of soluble Aβ42 is associated with how severe AD is. Aβ42
normally spreads throughout the neuronal tissue until it hits high enough levels that it then
aggregates and forms fibrils and eventually plaques.38 It has been demonstrated that
Aβ42 trimeric and tetrameric oligomers are the most dangerous. These can attach to
synapses and lead to their dysfunction, and eventually lead to neuronal death.40 In order
to investigate the effects Aβ42, in one study, researchers created an artificial plaque by
the injection of pre-aggregated Aβ42 into the nucleus bacillus of Maynert (NBM) in the
brains of rats. They concluded that the injection led to the formation of amyloid-β plaques,
as well as astrocyte and microglial infiltration and activation. The injection also led to iNOS
and COX-2 expression, interleukin-1-β (IL-1- β) production, cholinergic neuron death, and
p38MAPK pathway activation. The artificial plaque produced demonstrated many
characteristics of the plaques found in AD brains.41 amyloid-β fibrils and mutant APP are
also linked to the formation of neurofibrillary tangles (NFT) in transgenic mouse models
in vivo.42–44 Despite the clear connection of deposition of amyloid-β to AD pathology, the
ACH is not without its weaknesses. Some studies have indicated that both amyloid-β and

5

NFT may be a reaction instead of a cause. Similar AD pathology in regards to amyloid-β
has been found in brains of survivors of traumatic brain injury (TBI)45,46 or with damage
inflicted to the nucleus basalis of rats.47 Altogether, ACH is supported by ample data and
a well-established hypothesis for the development of AD pathology.36
1.1.4. Tau hypothesis
The second hallmark of AD is NFT triggered by atypically phosphorylated tau. The
tau hypothesis states that abnormally or hyper-phosphorylated tau is the causative event
from which AD pathology originates. The major supporting evidence of this hypothesis is
the strong correlation of the spread of tau pathology and the development of cognitive
decline seen in AD.48 Specifically, the cognitive symptoms presented in AD patients
correspond functionally to regions of the brain burdened by NFTs.49 Additionally, some
studies have reported the presence of tau pathology before the deposition of the amyloidβ peptide.50,51 The center of this hypothesis, tau, is a microtubule-associated cytoskeletal
protein expressed throughout the CNS. Tau functions to regulate neurite outgrowth and
stabilize microtubules. When tau is phosphorylated by kinases such as glycogen
synthase kinase-3, its ability to stabilize microtubules is decreased.52 When tau is
hyperphosphorylated, it detaches from the microtubule of the cytoskeleton; this creates
paired helical filaments (PHFs) which triggers the formation of neurofibrillary tangles that
impede neuronal transport in AD and other tauopathies.53 The exact trigger which leads
to tau hyperphosphorylation is not well established. However, studies have found multiple
contributing factors. One study demonstrated that administration of cytokine IL-6 to
hippocampal neurons could elicit an increase in the hyperphosphorylation of tau with
dependence on cdk5/p35, which is a complex of cyclin-dependent kinase 5 and activator
6

p35.

54,55

Despite the distinct hypotheses, there have been unifying theories for the role

in amyloid-β and NFTs in the pathology of AD that propose possible explanations for
discrepancies in either theories. 48,56
The involvement of both of these AD hallmarks and the failure of the immune
system to correct these insults is the major contributing factor of the neuronal atrophy
seen in AD. Additionally, they provoke a chronic and damaging cycle of inflammatory
response from the innate immune system.2,57
1.2 Multiple Sclerosis
1.2.1 MS History and Disease Presentation
Between the late 1700s and early 1800s Multiple Sclerosis (MS) was first
described in separate accounts by its clinical presentation and a depiction of its
characteristic plaques by Robert Carswell and Jean Cruveilhier.58 It wasn’t classified as
a distinct disease until 1868 when pathologist Jean-Martin Charcot connected the
histopathological changes from autopsies of MS patients with their clinical symptoms.59,60
Multiple sclerosis is an autoimmune disease characterized by sclerotic lesions in the brain
and spinal cord. The clinical signs of the disease are limb weakness and numbness,
bladder dysfunction, fatigue, depression, mood swings, and blurred vision. The disease
is also often characterized by an exacerbation of symptoms with higher temperatures,
known as Uhthoff’s phenomenon.20,61 There are multiple different types of MS which are
distinguished by the progression of symptoms and the presence of relapses and
remissions. The most common type of MS diagnosed in patients initially, 80%, is
relapsing-remitting MS. This is characterized by symptoms lasting days to months
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followed by remission in which a patient is symptom-free until the next relapse.62 The
second type of MS, secondary-progressive, is defined by a slow progression in severity
of symptoms and can include relapses. The third type of MS, primary-progressive, does
not have relapses and remissions but instead a continuous progression of symptoms.
Finally, 5% of patients initially diagnosed with MS are diagnosed with progressiverelapsing MS. Progressive-relapsing MS, the rarest form of MS, is characterized by
symptom flare-ups and a continuous decline and may or may not include remissions. 63
Risk factors for the development of MS include genetic mutations to the human leukocyte
antigen (HLA) gene which encodes a cell surface antigen presenting protein (major
histocompatibility complex)64 and

genes important for cytokine pathways such as

interleukin-7 receptor.65 Another risk factor for MS is previous infection with the Epstein
Barr virus.66
1.2.2 MS Histopathology
MS is characterized by sclerotic plaques primarily in the white matter of the CNS.
These lesions often occur in the corpus callosum, lateral ventricles, brain stem, optic
nerves, and spinal cord.61 The plaques stem from the autoimmune demyelination of
neurons. The myelin is a highly lipid-based multilayer sheath that protects the axons of
neurons. The myelin sheath is produced and maintained by the oligodendrocyte glial cell.
Gaps in the myelin are left to form the nodes of Ranvier which the electrical signal uses
to travels down the axon by saltatory conduction.67 With demyelination, axonal injury or
altered nodal components along axon lead to disrupted signal transduction. This then can
lead to the symptoms seen during relapses in MS; symptoms continue until remyelination
can occur.68,69 Other characteristics of lesions in MS are glial scarring around plaques to
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block off inflamed tissue and infiltrated autoreactive leukocytes.68 Autoreactive leukocytes
are recruited to the CNS by chemokines expressed during neuroinflammation. 4
1.3 The Immune System and Neurodegenerative Disorders
The commonality among these neurodegenerative disorders is neuroinflammation.
Neuroinflammation is inflammation of the nervous system brought upon by the immune
system in order to remove the agent causing damage and promote healing. 2 When
exposed to disease-specific trigger, immune cells are activated and release proinflammatory factors. When chronically exposed to pro-inflammatory factors further
neuronal dysfunction and damage occurs and leads to the release of damage-associated
molecular patterns (DAMPs). DAMPs can then activate pattern recognition receptors
(PRR) of the innate immune system and continue the cycle of damaging
neuroinflammation.3,70
1.3.1 The Immune System
The immune system is divided into 2 categories, the innate and the adaptive
immune system. When confronted with foreign pathogens or damage, the innate immune
system responds immediately with its defensive repertoire. This response is quick and is
often not as specific as the adaptive immune system; damage and pathogens are
recognized by their molecular patterns.71,72 There are multiple key components of innate
immunity; one such category of innate immune cells are granulocytes which can release
cytotoxic and pro-inflammatory substances.73 Another component is complement that
functions to enhance phagocytosis of pathogens and damaged cells or form the
membrane attack complex (MAC) which can rupture cell membranes.74,75 Additionally,
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the natural killer cells support the innate immune system by the release of cytotoxic
substances or by inducing apoptosis.72 Another important cell for the innate immune
system is the macrophage, these large cells phagocytose cellular debris or pathogens as
well as secrete pro-inflammatory factors.76 Finally, dendritic cells, which primarily function
as antigen presenting cells,

can stimulate a response from the adaptive immune

system.77
The adaptive immune system serves to remember pathogens not already well
recognized by the innate immune system. After antigen presenting cells reach the lymph
nodes or spleen, this triggers the induction of clonal selection and expansion of B or T
cells which recognize the antigen. Mature B cells main function is to produce antibodies
to target pathogens for destruction or neutralization. T cells include CD4+ helper T cells
(Th) which regulate other immune cells and CD8+ cytotoxic T cells which can release
cytotoxins to lyse pathogens or infected cells and induce apoptosis with Fas-Fas ligand
interactions.78–80

These

leukocytes

recognize

antigen

presented

on

major

histocompatibility complexes (MHC). CD4+ T cells recognize antigen presented by MHC
type II by other leukocytes and CD8+ T cells can recognize antigen presented by MHC
type I by any nucleated cells.81,82 Other adaptive leukocytes include: natural killer T cells,
γδ T cells,72 regulatory B and T cells,83 and memory B and T cells.84,85 The innate and
adaptive immune work together to protect the body from infection and disease. However,
the immune system has limited access to some parts of the body.
1.3.2 The Immune System in the Central Nervous System
The central nervous system (CNS) was first depicted as being immune privileged,
meaning that the immune system has restricted access to the CNS. In the late 19th
10

century, Paul Ehrlick injected dyes intravenously and found that they stained all organs
with the exception of the spinal cord and brain. The reason for this was in fact the blood
brain barrier.86 In 1898, Ledwandowsky coined the term "blood-brain barrier," after he
found that neurotoxic agents had an effect on the brain only when injected directly into it,
instead of intravenously. 87 Multiple studies have demonstrated that the blood brain barrier
(BBB) functions to limit the trafficking of ions, molecules, and cells.

94-90

However, the

CNS is not completely immune privileged as it might appear; the CNS has resident innate
immune cells made up of glial cells and a lymphatics system that has been described.81
Back in 1869 the lymphatic system in the brain was first described as an apparent
connection between the brain and the cervical lymphatic system in rabbits and dogs.91
Despite numerous other experiments in the 40s and 60s describing lymphatics in the
brain,92,93 the idea that the brain was immune privileged persisted until more recent
studies by Louveau and colleagues on mouse brain lymphatics and of human brain
lymphatics by Reich were published.94,95 In addition to a lymphatic system, the brain has
its own immune cells, glial cells.81,96 Glial cells are one of the main type of cells that make
up the CNS and consist of microglia, oligodendrocytes, and astrocytes. They play
important roles in the maintenance of neurons, production of myelin sheath, and
protection of the CNS.96,97
1.3.3 Microglial Cells
In 1919, the “father of microglia” Pio del Rio-Ortega demonstrated the distribution
of microglia throughout the brain using silver carbonate and their ability to alter
morphology when confronted with a disease state.98 Microglia cells have since then been
described as the central nervous system’s first line of defense. They are important in
11

maintaining the homeostasis of tissues in the brain. They keep tabs on their environment
seeking signs of disturbed functional or structural integrity. To maintain and protect the
CNS, they can phagocytose worn-out cells, pathogens, or improperly formed synapses.
However, they are also involved in the pathogenesis of neurodegenerative diseases like
AD and MS.104-100In the AD brain, microglia are recruited from surrounding blood vessels.
They migrate and gather into dense neritic plaques.101 Despite recruitment to the plaques,
the number of microglial cells around the lesion does not correlate with amyloid-β
degradation and instead it actually contributes to the volume of plaques. Instead of
effectively executing their function, the removal of the insults, some studies report that
they actually promote the converting amyloid-β oligomers in the plaques into fibrils
(fibrillogenesis).32,102 Additionally, the microglia is involved in the pathogenesis of MS by
demyelination of neurons and phagocytosis of myelin. Following the phagocytosis of
myelin, the microglia further perpetuates MS pathology by antigen presentation to
autoreactive T cells.103
1.3.4 Astrocytes
Astrocytes have many physiological functions in the innate immune system as well
as structural. It is believed that they support the structure of the blood brain barrier, as
their lengthy cytoplasmic extensions enclose capillaries in the brain. They also maintain
homeostasis and regulate plasticity with the release of neurotransmitters and trophic
factors. To combat pathologies, astrocytes undergo astrogliosis, altering both structure
and function. When activated, astrocytes cease homeostasis maintenance duties and
may evoke nerve cell damage.104–106 Multiple studies have shown that amyloid plaques
and aggregated amyloid-β can activate astrocytes. The astrocytes then work to clear the
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amyloid-β in the brain and take in Aβ42 into granules in their cytoplasm. They do this
likely by either phagocytosis or endocytosis mediated by a receptor.105,107 Astrocytes also
work to remove non-fibrillar amyloid with metalloproteases such as insulysin and
neprilsin.57,108 The encasement and penetration of amyloid plaques by astrocytes with
their cytoplasmic extensions can lead to scarring. The distribution of astrocytes within the
cortex of AD brains appears to correlate with the breadth of the AD pathology.105 In MS,
the astrocyte contributes to disease pathology by inhibition of remyelination by the
formation of glial scar.103 Furthermore, activated astrocytes provide a source of cytotoxic
factors.109
1.3.5 Inflammation Signaling Pathway
When the brain is confronted with damage or infection of any sort, the innate
immune system uses inflammation as a defense. The purpose of inflammation is to
remove harmful irritants and to halt their destructive effects. In the brain, what signals
inflammation to occur is usually the accumulation of abnormal proteins or injured
neurons.110,111 Glial cells, and neurons have a myriad of PRRs that recognize these
DAMPs. These PRRs include receptor for advanced glycation end-products (RAGE), riglike receptors (RLR), toll-like receptors (TLR), AIM2-like receptors (ALR), C-type lectin
receptors, and NOD-like receptors.112 The signal transduction pathways triggered by
these PRRs elicit inflammation.113 One example of these PRRs, TLRs, are receptors that
can signal and activate protein kinases like p38-MAPK, IKKs, and JNK. These kinases
spark inflammatory responses by transcription factors, such as IRF3/7, AP-1, and NFκB.114,115 These inflammatory responses include the secretion of chemokines,
prostaglandins, oxygen radicals, and cytokines. Even though the purpose of inflammation
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is to remove toxins and insults, this inflammatory response can be harmful to the brain in
the case of chronic or irremovable insults.116-122
1.3.6 Cytokines and Chemokines
Cytokines are important for inflammatory and anti-inflammatory processes. In
general, anti-inflammatory cytokines antagonize the effects of pro-inflammatory
cytokines, such as decreasing the synthesis of pro-inflammatory cytokines, inhibiting
apoptosis, or inhibiting the secretion of harmful proteases like matrix metalloproteinases
(MMP). Anti-inflammatory cytokines include: IL-10, IL-4, and TGF-β-1.117 An imbalance
of higher pro-inflammatory than anti-inflammatory cytokines can lead to the amplification
of cytotoxic processes. If glial cells are activated for too long they can kill the neurons
surrounding them by releasing toxic products, such as nitric oxide, excitotoxins,
proteolytic enzymes like MMP, or reactive oxygen species (ROS). 118 Pro-inflammatory
cytokines secreted by glial cells can trigger this cycle and can activate complement
cascades,

cyclooxygenase enzyme, and inducible nitric oxide synthase (iNOS).

Additionally, activated microglia has been shown to produce chemokines, e.g.,
macrophage inflammatory protein-1alpha (MIP-1alpha), monocyte chemoattractant
protein-1 (MCP-1), and IL-8.111 Chemokines are responsible for the recruitment of
immune cells to the site of inflammation. Therefore, they are responsible for the extent or
spread of the local inflammation.124,71
1.3.7 Innate immunity and Inflammasomes
One of the innate immune systems major contributors of proinflammatory
cytokines is the inflammasome. The inflammasome is a highly regulated multi-component
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PRR that responds to DAMPs or PAMPs for the purpose of protection against viral,
bacterial, fungal, parasitic infections, or any disruption in homeostasis.119 However
overactivation of the inflammasome is implicated multiple inflammatory diseases, such as
familial cold autoinflammatory syndrome, type II diabetes mellitus, Crohn’s disease, and
vitiligo-associated multiple autoimmune disease.120 Inflammasomes are characterized by
the domains which they contain. PYHIN family of inflammasomes consist of DNA-binding
HIN domain and an N-terminal pyrin (PYD) domain. This family includes the AIM2 and
IFI16 inflammasomes.121 The NLR family, for example, contains a nucleotide
oligomerization domain (NOD aka NACHT), a C-terminal leucine rich repeat (LRR)
domain, and a variable N-terminal domain. The N-terminal domain can vary from a PYD
domain in NLRPs to a caspase recruitment domain (CARD) in NLRC4. The NLR family
inflammasomes include: NLRC4, NLRP1, NLRP2, NLRP3, NLRP6, NLRP7, and
NLRP12.119 Inflammasomes without attached CARD use adapter protein apoptosisassociated speck-like protein containing a caspase-recruitment domain (ASC) which
contains both a PYD domain for associating with inflammasome and a CARD domain for
caspase recruitment. With recruitment and activation of the caspase the inflammasome
can cleave precursor cytokines into mature pro-inflammatory cytokines. The process is
highly regulated, the inflammasome protein can be modified by phosphorylation and
ubiquitination and requires a priming step to upregulate inflammasome components and
precursor cytokines.25 Of the inflammasomes, the best characterized and most implicated
in the progression of AD and MS is NLRP3.122-123
1.3.8 The NLRP3 Inflammasome
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Nod-like

receptor

pyrin

containing

3

inflammasome (NLRP3) belongs to the family of
nucleotide oligomerization domain (NOD)-like receptors
(NLR). NLRP3 consists of a LRR, NACHT, and PYD
domain (Figure 3).9 NLRP3 inflammasome also includes
the adaptor protein ASC and caspase-1. LRR functions
as a sensor for DAMPs and PAMPs. In its autoinhibition
conformation LRR interacts with the NACHT domain to
prevent association with ASC.8 The NACHT domain is
thought to play a role in oligomerization and has ATPase
activity. ATP binds at a conserved site among NLRPs,

Figure 3. The structure of
NLRP3
inflammasome.
Adapted from Lawlor et al.9

the Walker A motif GxxxxGK(S/T). The NACHT domain also contains a Walker B motif
necessary for ATP hydrolysis.124 The PYD domain mediates interaction with ASC and
ASC recruits caspase-1 with CARD domain. NLRP3 inflammasome activation can occur
in 2 ways canonical or non-canonical (Figure 4).125
1.3.9 Activation of the NLRP3 Inflammasome
In the canonical activation of NLRP3, the first step is the priming step for the
upregulation of NLRP3 inflammasome components, pro-IL-1-β, and pro-IL-18 by the
activation of NF-κB. Priming can occur via toll-like receptors (TLRs), such as MyD88 or
TNFR with TLR agonists, agonists for NOD-like receptors, or CLR. Additionally, cytokines
TNF-alpha and IL-1-β can also serve as priming promoters.126,127 The second step
involves the activation of NLRP3. The LRR senses DAMPs or PAMPs. These signals
include: extracellular ATP, potassium efflux, ROS, mitochondrial damage, pore-forming
16

Figure 4. Canonical and non-canonical pathways of activation of the NLRP3
inflammasome. Adapted from Man and Kanneganti.128

toxins, and nigericin. Another possible trigger for NLRP3 activation is the rupture of the
lysosome. Rupture of the lysosome can occur after the phagocytosis of amyloid-β,
aluminum salts, and silica crystals and is dependent on lysosome protease
cathepsin.127,128 After activation, the LRRs interaction with the NACHT domain opens up
and allows interaction with the PYD of ASC and ATP-dependent oligomerization. The
PYD domain on NLRP3 recruits ASC and continues to do so as initiation of speck
formation occurs. ASC nucleates caspase-1 filaments which then recruits local enzymes
for trans-autocleavage of caspase-1 into subunits p10/p20 tetramer. Activated caspase-
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1 can then process pro-IL-1-β and pro-IL-18 into proinflammatory cytokines IL-1-β and IL18.8,129
Non-canonical activation occurs when gram-negative bacteria activate TLRs which
in turn activate NF-κB. In addition to transcription of the NLRP3 inflammasome
components and cytokine precursors, interferon regulatory factors IRF-7 and IRF-3 genes
are also transcribed. IRF-7 and IRF-3 then form a complex and trigger IFN-alpha/beta
secretion. IFN-alpha/beta then activates the IFNAR1/IFNAR2 receptor which activates
the JAK/STAT pathway, increasing the expression of pro-caspase-11. Activation of
caspase-11 is not well established but it is believed that either procaspase-11 can be
auto-activated on its own or the gram-negative bacteria activates a receptor which
downstream can activate caspase-11. Activation of caspase-11 can then induce
inflammatory cell death (pyroptosis) and activate the NLRP3 inflammasome caspase-1
pathway.126,130 Another non-canonical pathway that may activate NLRP3 is via caspase8. In some macrophages, after activation with fungal cell wall component, β-glucan,
caspase-8 with Fas-associated death domain (FADD) can both prime and activate
NLRP3.125
1.3.10 Downstream Effects of Activation of the NLRP3 Inflammasome
Pro-inflammatory cytokine IL-1-β is of the major class of IL-1 cytokines. IL-1beta
has been demonstrated to elicit inflammatory cascades through multiple pathways. IL-1β can simulate inducible nitric oxide synthase (iNOS) via transcription factor NF-κB and
CCAAT-enhancer binding protein (C/EBP) activation.131,132 It can also induce the
production of granulocyte-macrophage colony-stimulating factor (GM-CSF).133,134
Additionally, IL-1-β can trigger production of IL-6 which can then activate microglia, and
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promote astrogliosis.135 The second cytokine produced by activation of NLRP3
inflammasome, IL-18, is also a key player in neuroinflammation. This cytokine appears to
exacerbate AD pathology by regulating the tau kinases GSK3-β and Cdk5. Additionally,
levels of beta secretase enzyme BACE-1, subunit of gamma secretase n-terminal
fragment of presenilin-1, APP, and adaptor protein Fe56 were found to be increased by
IL-18.136 Furthermore, IL-18 can trigger production of interferon-gamma (IFN-gamma)
from helper T-cells Th1.137 IFN-gamma, a pro-inflammatory cytokine can in turn induce
production of nitric oxide.138
1.3.11 Dysregulation of the NLRP3 Inflammasome in Neurodegenerative Disorders
Recently numerous studies have suggested the essential role of the NLRP3
inflammasome in many human diseases including myocardial infarction, traumatic brain
injury, diabetes type II, gout, AD, and MS. In an effort to better demonstrate the direct
impact of NLRP3 inflammasome activation in these disease processes two well
documented examples, AD and MS, will be briefly further discussed.
In AD, amyloid-β has been implicated to be a trigger for activation of NLRP3. In
particular, soluble amyloid-β is phagocytosed by microglia leading to destabilization of
the lysosome, releasing cathepsin B into the cytosol and triggering NLRP3 activation.
Additionally, NLRP3 activation can occur when the amyloid-β oligomers elicit a potassium
efflux from neurons.116 Aside from activation of NLRP3 by AD hallmarks, NLRP3
inflammasome activation is implicated in the impediment of phagocytosis of amyloid-β by
microglia. When microglia from APP/PS1/NLRP3 -/- were compared with microglia from
APP/PS1 mice it was found that the microglia from the APP/PS1/NLRP3 -/- mice were
significantly more efficient at phagocytosis of amyloid-β. Additionally, the level of amyloid19

-β aggregates in APP/PS1/NLRP3 -/- were diminished without a change in total
APP.139,140
Multiple Sclerosis is another neurodegenerative disease closely associated with
the NLRP3 inflammasome.141 Caspase-1 and IL-1-β was found elevated in plaques in MS
patients and elevated alongside cytokine IL-18 in peripheral blood mononuclear cells.145146,7

In experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, the

NLRP3 inflammasome demonstrated a role in the recruitment of T-helper cells to the
CNS.

NLRP3-/- mice displayed protection from development of EAE as well as

decreased infiltration of T cells into the CNS. Th17 cells in these mice exhibited decreased
expression of chemokine receptors CCR2 and CXCR6, important for infiltration of the
CNS.147
1.3.12

NLRP3

inflammasome

as

Novel

Target

for

the

Treatment

of

Neurodegenerative Disorders
Given the demonstrated role of NLRP3
inflammasome dysregulation in the development of
multiple human diseases, small molecules targeting
the NLRP3 inflammasome pathway represents an
innovative strategy to develop more effective

Figure 5. Chemical structure
of MCC950.147

treatments. Recently, several small molecule compounds have been reported to inhibit
the NLRP3 inflammasome pathway. Acrylate derivative NLRP3 inhibitor demonstrated in
vivo therapeutic potential for inflammatory bowel disease,144 ketone metabolite betahydroxybutyrate a specific NLRP3 inhibitor which was shown to block ASC
oligomerization,145 and selective NLRP3 inhibitor CY-09 which prevented death in a
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mouse model of CAPs.146 The most potent however, MCC950, a diarylsulfonylurea
compound, was discovered to inhibit the processing of IL-1-beta (IC50 7.5 nM) (Figure
5).147 Additionally, MCC950 demonstrated selectivity to NLRP3 among other
inflammasomes by failing to inhibit IL-1-β secretion by AIM2 and NLRC4 after
administration of selective activators dsDNA and bacteria Salmonella typhimurium to
BMDMs respectively. Furthermore, MCC950 has shown effectiveness in vivo in a mouse
model of Muckle-Wells Syndrome which is cryopyrin associated periodic syndrome
(CAPS) that involves a mutation to NLRP3 and results in increased levels of IL-1-β and
IL-18.151 In general, the exact mechanism of action of these NLRP3 inhibitors is not well
established
.
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Chapter 2: Preliminary Data
2.1 Design of Sulfonamide-based Small Molecule Inhibitors of the NLRP3
inflammasome
Given the success of selective NLRP3 inflammasome
inhibitors in in vivo models, the NLRP3 inflammasome appears
to be a promising therapeutic target for the treatment of
neuroinflammation. Recently, Glyburide, the commonly used
anti-diabetic, has been shown to inhibit the NLRP3
inflammasome.148 Glyburide 1, is a commonly used drug to
treat type 2 diabetes, belonging to the class of sulfonylurea
Figure 6. Structures
of
Glyburide
and
Glipizide.148
antidiabetics which also includes
Glipizide 2 (Figure 6). Sulfonylurea
antidiabetics
binding to

treat

diabetes

by

and blocking K+ATP

channels of the beta cells in the
pancreas leading to depolarization
of membrane and influx of calcium
through
Figure 7. Inhibition of the production of cytokines
by glyburide and glipizide. BMDMs were primed
with LPS and pre-incubated with drug and
stimulated with ATP. A. IL-1β. B. IL-18. C. IL-6.
D. TNFα. Adapted from Lamkanfi et al.148

Ca2+

channels.

This

triggers the exocytosis of insulin
and subsequent lowering of blood
sugar.149 When

Glyburide

was

tested along-side the sulfonylurea antidiabetic drug, Glipizide, in mouse BMDMs, IL-18
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and IL-1β were dose dependently inhibited, while TNFalpha and IL-6 were not suppressed by Glyburide
treatments (Figure 7). This clearly indicated the specific
inhibition of the NLRP3 inflammasome pathway by
Glyburide. Notably, Glipizide did not show any effects
on the production of IL-1β and IL-18 under the same
experimental

conditions.

These

results

strongly

suggested that the observed inhibition on the NLRP3
inflammasome by Glyburide is independent from its
anti-diabetic

effects.

Additionally,

Glyburide

demonstrated dose dependent inhibition of cleavage of
caspase-1, indicating prevention of the NLRP3
inflammasome specific activation of caspase-1
(Figure 8). In addition to presented data, the study
also demonstrated that macrophage KATP channels
and the cyclohexylurea moiety on Glyburide is not

Figure 8.
Inhibition of
production
of
caspase-1
cleavage product p20. Black
arrows indicate pro-caspase-1
and white arrows indicate
cleavage product p20. Adapted
from Lamkanfi et al.148

needed for inhibition of NLRP3, further supporting
that the mechanism of action is not through its antidiabetic activity. Also, Glyburide
inhibited the NLRP3 inflammasome independently of P2X7 receptor but appeared to act
upstream of ASC and caspase-1 given that the activation of caspase-1 with adaptor ASC
by other means (Ipaf and NALP1b) was not affected by glyburide. However, the dose of
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glyburide needed to inhibit NLRP3 in vivo would result in lethal hypoglycemia, thus limiting
further development of glyburide as a NLRP3 inflammasome inhibitor.148
Based on the structure of glyburide, our group designed a
sulfonamide analog, JC-21, and evaluated its inhibitory activity on
the NLRP3 inflammasome (Figure 9). For the activity assay of
caspase-1, HL-1 cells (immortalized mouse cardiomyocytes) were
pretreated with JC-21 followed by priming with LPS and activation of
the NLRP3 inflammasome with ATP. The caspase-1 activity was
then determined by the cleavage of a fluorogenic substrate and

Figure 9.
Structure of
JC-21.11

cytotoxicity was determined with the Trypan blue exclusion method.
The results demonstrated that JC-21 retained inhibitory activity on

caspase-1 and rescued
HL-1 cells from LPS/ATP
treatment

induced

cell

death (Figure 10). Our
studies also established
that JC-21 is a selective
inhibitor to the NLRP3
inflammasome
activity

was

when NLRC4

as

no

observed

Figure 10. Inhibition of caspase-1 activity and cell death
by JC-21 A. Caspase-1 activity measure by CaspASE
(Promega, Madison, WI). B. cell death determined by
Trypan exclusion method. Adapted from Marchetti et al.
11
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Figure 11. Inhibition of caspase-1 activity and cell death by JC-21 given activators of
inflammasome AIM2 and NLRC4. A. Caspase-1 activity measure by CaspASE
(Promega). B. cell death determined by Trypan exclusion method. Adapted from
Marchetti et al.11
or

AIM2

inflammasome

was

activated

with

flagellin

or

poly-deoxyadenylic-

deoxythymidylic acid sodium salt (Poly(dA:dT)), respectively (Figure 11). Notably, our
studies demonstrated that JC-21 inhibited the production of IL-1β from BMDM cells from
NLRP3A350V/CreT transgenic mice. This specific mutation is heavily associated with MuckleWells Syndrome (MWS) and Familial Cold Autoinflammatory Syndrome (FCAS), one of
the cryopyrin-associated periodic syndromes (CAPS) characterized by overactivation of
the NLRP3 inflammasome due to mutations to NLRP3. This mutant NLRP3 can
spontaneously oligomerize into the active NLRP3 inflammasome without the need of
activation signals. Collectively, the results from selectivity studies and the BMDMs
carrying the mutant NLRP3 suggest that JC-21 may directly target the NLRP3
inflammasome complex.10,11

25

2.2 JC-21 Analog, JC-171, Inhibits the NLRP3 Inflammasome
Although JC-21 showed promising activity as a novel NLRP3
inflammasome inhibitor, solubility was observed as an issue during
the experiments. To improve aqueous solubility and also to evaluate
whether structural modifications on the sulfonamide moiety are
tolerated, a hydroxy group was introduced by the hydroxamic acid
analog JC-171 (Figure 12). The Log P for JC-21 and JC-171 is 0.80
and 0.19, respectively, confirming the increased polarity of JC-171.

Figure 12.
Structure of
JC-171.12

Our studies in mouse macrophage J774A.1 cells demonstrated a
dose-dependent inhibition of IL-1β by treatment with JC-171 with an IC50 of 8.5 ± 1.6 μM
but no inhibition of cytokines IL-6 and TNFα (Figure 13).12

Figure 13. Inhibition of production of cytokines by JC-171. A. Dose-dependent
response of inhibition of IL-1β. B. Inhibition of control cytokines IL-6 and TNFα.
Adapted from Guo et al.12
Prior studies employing constitutively active NLRP3 suggested that this chemical
scaffold might function as an inhibitor by blocking the formation of the NLRP3
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inflammasome complex. In order
to

determine

this,

immunoprecipitation

a

(IP)

costudy

was done using primary BMDMs
stimulated with LPS and ATP.
Shown in Figure 14, treatment of
Figure 14. Inhibition of ASC association to
NLRP3 by JC-171. NLRP3 and ASC were
visualized via immunoblot (left). Ratio of band
intensity of ASC to NLRP3 was calculated (right).
Adapted from Guo et al. 12

BMDMs with JC-171 blocked the
association of ASC to the NLRP3
protein

during

activation.

This

provided further evidence to the
hypothesis that this novel chemical scaffold inhibits the NLRP3 inflammasome directly.12
Considering neuroinflammation is a critical component of MS pathology and the
demonstrated role of the NLRP3 inflammasome in MS, 150–152 JC-171 was tested in
experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, for evidence
that NLRP3 inhibitors can serve as potential
therapeutic agents for MS. The therapeutic
potency of JC-171 was tested alongside
MCC950

by

administration

of

either

compound starting when the clinical scores
of individual mice have reached 1 (flaccid
tail).

Subsequent

clinical

scores

were

assigned every other day based on the
extent of paralysis of the mouse. Regardless
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Figure 15. Clinical scores of EAE mice
dosed with either 10 mg/kg of JC-171
(green line), 10 mg/kg of MCC950 (red
line), or vehicle (black line). Adapted
from Guo et al.12

of the use of a low dose of JC-171 (10 mg/kg) in mice,
JC-171 significantly attenuated EAE progression when
compared with control (Figure 15). JC-171 exhibited
comparable in vivo therapeutic activity with MCC950,
an NLRP3 inflammasome inhibitor that was recently
reported to block EAE development.153 Additionally,
treatment with JC-171 also led to a substantial
decrease in the frequency of MOG35−55-specific Th17
cells in both the spleen and spinal cords of EAE mice
(Figure 16). Consistent with the reduction in clinical
Figure 16. Determination of
demyelination of spinal cord
and frequency of MOG
specific Th17 cells in the
spinal cord and spleen. A. The
frequency of IL-17A+CD4+
Th17 cells in the spinal cord
and spleen. B. Demyelination
(indicated by black squares) in
the spinal cord. Adapted from
Guo et al.12

score, the histological analysis demonstrated that
demyelination was reduced in the white matter of the
spinal cords from EAE mice treated with JC-171, as
indicated by Luxol fast blue staining (Figure 16).
Collectively, the in vitro and in vivo results of JC-171
and JC-21 suggest that this chemical scaffold is a
promising template for the development of small

molecule inhibitors for the NLRP3 inflammasome.11,12 Furthermore, this data also
encourages the further development of JC-171 and analogues as potential therapeutic
agents for MS as well as other inflammatory diseases involving the NLRP3
inflammasome. 12
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Chapter 3: Mechanistic Studies of Sulfonamide-based small molecule NLRP3
inflammasome inhibitors
Our studies suggested that analogs derived from this sulfonamide scaffold may
directly interfere with the formation of the NLRP3 inflammasome complex. This was
based on the fact that 1) inhibitors block ASC recruitment;12 2) they do not directly inhibit
caspase-1 activation as NLRC4 and AIM2 pathways are not affected;11 and 3) they block
the release of IL-1β and the activation of caspase-1 in macrophages expressing
constitutively active NLRP3 from mutant mice.11,12 However, it is not clear how the
inhibitors based on this chemical scaffold interfere with the formation of such protein
complex. It is therefore our goal in this research project to elucidate the mechanism of
action (MOA) for this chemical scaffold as direct NLRP3 inflammasome inhibitors by
biophysical, biochemical and computational studies. Specifically, the microscale
thermophoresis (MST) assay was utilized to determine the binding affinity of our
compounds to various components of the NLRP3 inflammasome. Mechanistic studies
involving the ATPase of the protein and molecular modeling were also employed to
determine the possible binding site for our compounds. Finally, with liquid
chromatography-mass spectrometry, the BBB penetration of our compound was
measured.
3.1 MST Assay
3.1.1 Introduction to MST
To measure the affinity of a direct interaction of our compounds with various
components of the NLRP3 inflammasome, MST was employed. MCC950, a known

29

inhibitor that targets the NLRP3 inflammasome pathway was tested alongside our
compounds to determine whether there was a shared MOA. As a relatively new
technique, MST is used to quantify biomolecular binding interactions. MST uses a laser
to create a thermal gradient in each capillary with fluorescently tagged-protein and varying
concentrations of the non-labeled ligand or protein. The MST uses any change in
thermophoresis caused by a change in the hydration shell around the fluorescent protein,
change in size, charge, or conformation of the protein from binding interactions. Such
binding interaction will change the movement of the protein in the thermal gradient and
then can be detected by the fluorescence from the tagged-protein. Consequently, this
enables a quantification of bound versus unbound protein to the ligand and therefore
binding affinity (KD) of the ligand to protein can be calculated.154
The binding check feature of the MST compares the normalized fluorescence
(Fnorm) of labeled protein to the Fnorm of the labeled protein with ligand. Additionally,
the binding check feature allows determination of any interfering fluorescence from buffer
or ligand. The binding check can quickly determine if any binding can be detected without
consuming as much protein as the binding affinity test. For the binding affinity test, the
protein concentration is kept constant with 12 different concentrations of unlabeled ligand
in each capillary. From the ∆Fnorm calculated in each capillary, a binding dependent
sigmoidal curve should appear in the case of a binding event. The fraction bound can
then be determined from the ∆Fnorm curve and a KD can be determined.154,155
Initial fluorescence in each capillary is measured to ensure each value does not
vary more than 10%. If initial fluorescence varies it could indicate either poor pipetting
technique or ligand induced fluorescence changes; in either of these cases an accurate
30

KD cannot be determined. Additionally, aggregation and adsorption to the capillary wall
of the fluorescent protein is also determined to ensure a good quality sample. In addition
to these automatic quality control checks, a few rules need to be applied when analyzing
data to determine if the results can be reliably distinguished from noise. The amplitude of
the noise in the baseline should be at the least 3 times less than the response amplitude
between bound and unbound Fnorm values. Finally, as determined through
experimentation with known binding interactions, the cut off response amplitude between
bound and unbound should be ≥ 5 for reliable and reproducible results.155
3.1.2 MST Results and Discussion
3.1.2.1 Binding interaction with the recombinant and full length NLRP3 protein
We first tested the binding interactions of JC-171 and MCC950 with human
recombinant full-length NLRP3 protein by MST. The NT-647 labeled full length NLRP3
protein was tested at a final concentration of 50 nM. JC-171 was tested initially at 500
μM with the binding check feature. The excitation was set to 40% for sufficient
fluorescence counts and the power was set to medium for the best signal to noise ratio.
The results revealed a response amplitude of 8.1 and a signal to noise ratio of 10. This
clearly indicated a binding interaction between JC-171 and the NLRP3 protein. Following
the binding check, a binding affinity assay of JC-171 to NLRP3 was then tested in triplicate
at a range of 500 uM -122 nM. The results established a KD of 2.54 ± 0.500 μM, consistent
with its IC50 for inhibition of the production of IL-1β. Notably, when MCC950 was tested
in MST assays, no binding interaction was observed (Figure 17, 18). The results are in
agreement with the published data to show that MCC950 does not interfere with NLRP3-
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NLRP3 interactions.153 The binding affinity results of JC-171 and MCC950 strongly
suggest that they have distinct MOAs to inhibit the NLRP3 inflammasome.

Figure 17. MST assay for affinity of JC-171 for fluorescently tagged (NT-647) full
length NLRP3. A. Binding check for JC-171. B. Calculated fraction bound doseresponse of binding interaction of JC-171 and full length NLRP3.
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Figure 18. MST assay for affinity of MCC950 for fluorescently tagged (NT-647)
full length NLRP3. A. Binding check for MCC950. B. Calculated Fnorm doseresponse of MCC950.

3.1.2.2 Binding interaction with the mutant NLRP3 (K232A) Protein
To further identify the binding domain within the NLRP3 protein for our compounds,
a fluorescently labeled mutant NLRP3(K232A) was used to explore any change in binding
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affinity for JC-171. K232 is one of the amino acids in the walker A motif of the nucleotidebinding domain (NACHT). This amino acid coordinates with the gamma phosphate of
ATP and is essential for ATPase activity.124 The binding check studies showed a

Figure 19. MST assay for affinity of JC-171 for fluorescently tagged (NT-647)
full length NLRP3 mutant (K232A). A. Binding check for JC-171. B. Calculated
fraction bound dose-response of JC-171.
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response amplitude > 5 and a signal to noise ratio of 5, suggesting binding interactions
of JC-171 with NLRP3(K232A). Further binding affinity studies established a KD of 4.58 ±
2.13 μM (Figure 19), comparable to the binding affinity from the full length NLRP3 protein.
These results suggest that the binding site for our compound is not overlapping with the
ATP binding site.
3.1.2.3 Binding interaction with the LRR Component of the NLRP3 protein
To further investigate which domain of NLRP3 our inhibitors might bind to, MST
assays were conducted using the LRR fragment of the NLRP3 protein. In this study, the
analogs of JC-171: GA3, HL-12, and HL-16 were tested for binding affinity. In our cellular
assays, HL-12 and HL-16 are potent inhibitors on the release of IL-1β with IC50s of 0.670
µM and 1.30 µM, respectively. Additionally, MCC950 was also tested for binding affinity.
The NT-647 labeled LRR component of NLRP3 protein was used at a final concentration
of 50 nM. The MST assay conditions were set identical to the ones used in full length
NLRP3 protein. GA3 was tested in triplicate with a range of 1 mM to 0.15 uM (Figure 20).
MCC950 was tested in triplicate at a range of 200 to 0.07uM (Figure 20). No binding
interactions were observed for both GA3 and MCC950 under the current experimental
conditions. This may suggest that our compounds do not bind to the LRR domain within
the NLRP3 protein. Similarly, we did not detect binding interactions for analogs HL-12
and HL-16 (Figure 21). Collectively, the results strongly suggest that there are no binding
interactions for the tested compounds from our studies to the LRR domain of the NLRP3
protein.
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Figure 20. MST assay for affinity of GA3 and MCC950 for fluorescently tagged (NT647) NLRP3 LRR segment. A. Calculated Fnorm dose-response curves of GA3. B.
Calculated Fnorm dose-response curves of MCC950
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Figure 21. MST assay for affinity of JC-171 analogs for fluorescently tagged (NT-647)
NLRP3 LRR segment. A. Calculated Fnorm dose-response curves of HL-12. B.
Calculated Fnorm dose-response curves of HL-16.
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3.1.2.4 Binding Interactions to the ASC Protein
The NLRP3 inflammasome is a multiprotein complex with at least three proteins:
NLRP3, ASC, and caspase-1. Since strong evidence has been presented to disregard

Figure 22. MST assay for affinity of compounds for fluorescently tagged (NT-647) ASC
protein. A. Calculated Fnorm dose-response curves of GA3 from MST assay. B.
Calculated Fnorm dose-response curves of MCC950 from MST assay.
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binding interactions with caspase-1 as the MOA, further investigation into the binding
interactions with ASC was investigated to better establish that interaction with ASC was
not the MOA of our compounds. To evaluate whether our compounds bind to the adapter
protein ASC, MST studies were conducted for GA3 and MCC950. The NT-647 labeled
ASC protein was tested at a final concentration of 10 nM. The MST excitation was set to
95% for sufficient fluorescence counts and the MST power was set to medium for the best
signal to noise ratio. As shown in Figure 22, a binding curve might be observed for GA3
to ASC protein. However, the response amplitudes remained below 5 and poor signal to
noise ratios were observed. This indicated that the signals could not be distinguished from
noise. MCC950 was also tested in a range of 200 to 0.07 uM and no binding interaction
was observed as well under the experimental conditions (Figure 22).
3.2 Direct Binding to NLRP3
In the interest of supporting data for direct binding to the NLRP3 protein as being
the mechanism of action of the compound, a
pull-down assay coupled with immunoblotting
was performed by Dr. Liu He. J774A.1 primary
mouse macrophage cells were pretreated with
LPS to induce production of NLRP3 protein. Cell
lysates were incubated with control compound
Figure 23. Immunoblot of J774A.1
lysate incubated with biotin probes
of CY-09 or JC-171 analog (HL-79)
using antibody specific for NLRP3.
Positive control is CY-09 probe
known to bind to NLRP3 and
negative control is cell lysates
without probe.

CY-09-probe,

a

positive

control

that

demonstrated ability to bind to NLRP3 in pull
down assay,146 or a biotin conjugated probe
analog of JC-171 compound, HL-79. Lysates
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were incubated with beads to capture biotin probes, washed, and then boiled and
resultant protein run on SDS-PAGE followed by an immunoblot with primary antibody for
NLRP3 and secondary antibody with attached HRP for visualization (Figure 23). HL-79
probe captured NLRP3 better at 1 μM than positive control CY-09 probe at 5 μM. This
data further supported direct interaction with the NLRP3 protein as being the mechanism
of action of these compounds for inhibition of the NLRP3 inflammasome.
3.3 ATPase activity of the NLRP3 protein
3.3.1 Introduction to the NLRP3 ATPase
Due to the conserved nature of the ATP binding pocket among the NACHT
domains of inflammasomes, it would be of importance to determine whether our
compounds interfere with the ATPase activity of NLRP3, given the fact that our binding
studies strongly suggest the interaction of our compounds with the NACHT domain. The
ATPase activity study will also support the results of the binding interaction of JC-171 to
the mutant NLRP3 (K232A). Furthermore, despite the importance of K232 to ATP binding,
other conserved residues are also involved in ATP binding of the walker A motif.156
Therefore, the investigation of the ATPase interference by our inhibitors will provide
valuable information on whether or not there is any interaction with our compounds and
the ATP binding pocket. In order to determine the ATPase activity of NLRP3 protein, the
ADP-Glo assay (Promega, Madison, WI) was employed.
3.3.2 ADP-Glo Results and Discussion
After incubation of compounds with human recombinant NLRP3 protein following
references protocol,144 ATP was the added for hydrolysis. The positive control contained
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only protein and ATP to determine the percent conversion of ATP to ADP. The negative
control was a blank with no protein or ATP to determine if there was any background
signal. A standard curve of ATP and ADP from 250 uM of ADP (100% conversion) to 0
uM of ADP (0% conversion) and the corresponding concentrations of ATP 0 uM to 250
uM was established (Figure 24). The r² of the fit was > 0.991. The assay was done in
triplicate alongside a standard curve for each repeat and the signal from the samples was
normalized as a percentage of the positive control to better visualize percent inhibition of
the ATPase.
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Figure 24. Representative standard curve tested samples from one assay of the
triplicate performed. The equation for the fit and r² are displayed in the upper righthand corner of the graph.
As shown in Figure 25, no inhibition on the ATPase activity of NLRP3 was observed for
all of the tested compounds. Combining the results of binding interaction with mutant
NLRP3 (K232A), the results suggest that our compounds do not bind to the ATP binding
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pocket within the NLRP3 protein. However, our results suggested a relatively low
conversion rate of ATP (≤ 5%) by the ATPase of NLRP3 under the current experimental
conditions. Further testing is warranted with a higher concentration of NLRP3 to decisively
conclude none of the compounds interfere with the ATPase activity.
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Figure 25. ADP-Glo assay to determine inhibition of ATPase activity of the NLRP3 protein by
JC-171 and other analogs. Luminescence signals were normalized as percentage of the
positive control.
3.4 Molecular Modeling studies
3.4.1 Introduction to Molecular Modeling of the NLRP3 Protein
The protein binding experiments and ATPase activity studies indicated that JC171 binds to the NLRP3 protein but not to the adaptor protein ASC of the NLRP3
inflammasome. The results further suggested that our compound may bind to the NACHT
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domain of NLRP3 protein, but without interfering with ATP binding. To further support this
conclusion and visualize the possible binding sites of our compounds to the NACHT
domain of NLRP3, a homology model of the NACHT domain was constructed from the Xray crystal structure of NLRC4 with MODELLER.157,158 NLRC4, Nod-like receptor card
domain containing protein, is another member of the NLR family that recruits caspase-1.
Unlike NLRP3, NLRC4 contains an N-terminal CARD domain. Additionally, NLRC4
inflammasome is activated by flagellin and type III secretion systems of gram negative
bacteria instead of extracellular ATP and other DAMPs that activate NLRP3.159 The
structure of NLRC4 was chosen mainly based on the sequence identity and similarity of
its NACHT domain to the NACHT domain of NLRP3 protein. Homology models generated
using template structure were filtered by Ramachandran plots. To further validate the
model, ADP from the crystal structure was docked back into the nucleotide binding pocket
of the model and HINT scores calculated to determine if hydropathic interactions were
favorable.160 JC-171 was docked with GOLD and HINT score was calculated to gauge if
the interaction was favorable.161
3.4.2 Results and Discussion
3.4.2.1 Sequence Alignment
The sequence alignment was conducted using emboss needle pairwise sequence
alignment. This sequence alignment program uses the Needleman-Wunsch alignment
algorithm to identify the best alignment over entire length of the sequences. The results
demonstrated an identity of 24.1% and similarity of 41.2%. Gaps were measured to be
19.4% and the score was 161.162 The score is the sum of matches minus the penalty for
gaps opened (Figure 26). The percentage of identity does not meet the rule of thumb for
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homologs, which is ≥ 30%.163 However, it is well established that these two proteins are
related through the NLR family and the NACHT domains of both proteins are share similar
functions.129 Furthermore, when the sequences of the ATP binding pocket of these
proteins compared, the alignment showed a sequence identity of 50% and a similarity of
75%. The alignment was therefore used to generate homology models through
MODELLER.157

Figure 26. Sequence alignment of mouse NLRC4 NACHT domain with human NLRP3
NACHT domain by emboss needle pairwise sequence alignment. Identical amino acids
between the sequences are indicated with a dark grey box. Light grey boxes are used to
indicate similar amino acids between the sequence.
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3.4.2.2. Structure and Validation
The models were compared by Ramachandran plots. A Ramachandran plot is
important for determining the structure and conformation of the protein by comparing the
dihedral angles between Cα and C (ψ) and between N and Cα (φ) of the backbone of the
protein. Model 70 indicated a beta sheet and right-alpha helix structure and had some
indication of left-handed alpha helix
structure. The model in general is
comparable to the Ramachandran
plot of template structure NLRC4
and had few violations (Figure 27).
The

models

with

the

best

Ramachandran plots were next
compared by docking the ADP from
the crystal structure of NLRC4 back
into the nucleotide binding pocket
(Figure 28). In model 70, ADP
formed H-bond interactions with
amino acids Lysine 232, Threonine
233, Glycine 229, Histidine 522, and
Figure 27. Ramachandran plots of NACHT
domain. A. NACHT domain of NLRC4. B.
Homology model 70 of NACHT domain of
NLRP3. Red dots indicate violations compared
to ideal.

Arginine

351

(Figure

29).

Specifically, the beta phosphate of
ADP formed H-bond interactions
with Lysine 232, Glycine 229, and
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Histidine 522. The alpha phosphate formed H-bond interactions with Lysine 232,
Threonine 233, and Arginine 351. Amino acids Lysine 232, Threonine 233, and Glycine
229 correspond with the amino acids Lysine 175, Serine 176, and Glycine 172 of the
NLRC4 nucleotide binding pocket where ADP forms interactions within the template
crystal structure. Another amino acid that ADP binds to in model 70, Histidine 522,
corresponds with the amino acid Histidine 443 in the structure of NLRC4 to which ADP
binds.158 Histidine 522 is a conserved amino acid in the winged helix domain of NACHT
domain and has been suggested to
be important for the stabilization of
the autoinhibition conformation.124 In
addition to interactions with the
walker A motif and winged helix
domain, ADP formed a H-bond
interaction with Arginine 351 of the
highly conserved sensor 1 motif. This
motif is believed to coordinate with
the nucleotide binding.15 In addition to
forming

hydrogen

bonds

with

important amino acids for nucleotide
Figure 28. ADP docked in the ATP binding
pocket of homology model 70. ADP is
indicated in red.

binding,
favorable

ADP also demonstrated
hydropathic

interactions

with a HINT score of 5,814.160 Interactions that contributed to this score were: 5.468e+03
for hydrogen bonds, 6.442e+03 for acid/base interactions, and 1.257e+03 for hydrophobic
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interactions. Unfavorable interactions that contributed to this score were: -1.499e+03 for
acid/acid

interactions,

-1.766e+03

for

base/base

interactions,

and

-4.087e+03

hydrophobic/polar interactions. Based on these observations, Model 70 was chosen for
further docking studies.

Figure 29. ADP docked into ATP binding pocket. ADP interacted with amino acids of
the Walker A motif: Glycine 229, Lysine 232, and Threonine 233. ADP also formed
hydrogen bond with conserved amino acid Arginine 351 of the sensor 1 motif, and
Histidine 522.
3.4.2.3 Docking studies of JC-171 and other analogs
JC-171 and other analogs were docked into model 70 with GOLD v. 5.4. The
binding pocket in which the analogs consistently docked with the highest CHEMPLP
scores was located next to the nucleotide binding domain. Although this domain does not
overlap entirely with the ADP binding pocket, it does share one amino acid at the edge of
the binding pocket, Arginine 351 of the sensor 1 motif (Figure 30). Other amino acids that
formed H-bond interactions with JC-171 were Arginine 237, Glutamine 509, and
Isoleucine 521 (Figure 31). The CHEMPLP for JC-171 docked in the pocket was 70.53.161
The HINT score was calculated as 880.6.160 Favorable interactions that contributed to this
score include: 2.247e+03 from acid/base interactions, 9.323e+02 from hydrogen bond
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interactions, and 4.830e+02 from hydrophobic interactions. Unfavorable interactions that
contributed to this score include: -1.569e+03 hydrophobic/polar interactions, -9.325e+02
base/base interactions, and -2.808e+02 acid/acid interactions.

Figure 30. JC-171 docked into the pocket next to nucleotide binding pocket. Walker A
motif highlighted in red. ADP is depicted as orange molecule and JC-171 is depicted
as cyan molecule.
Although Arginine 351 has been implicated to coordinate with the nucleotide in
ATP binding, it’s role in ATP binding to the NLRP3 protein is not well established. 124 Due
to its close proximity to the ATP binding pocket and interaction with the winged helix
domain, the binding pocket where JC-171 and other analogs docked into may represent
an allosteric site that supports the autoinhibition conformation and prevents
oligomerization of the NACHT domain.15 Although close to the nucleotide binding pocket,
JC-171 does not bind in the binding pocket or to any amino acids in the Walker A motif.
This is consistent with the MST binding results of JC-171 with mutant NLRP3 (K232A).
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The binding of JC-171 to Arginine 351 does not conclusively assert that JC-171 should
inhibit ATPase activity, especially given the unclear role of this residue in ATP binding.
But this does raise the question that a higher concentration of NLRP3 protein and/or
robust ATPase activity needs to be investigated to rule out the possibility that JC-171 will
interfere with the ATPase activity of NLRP3 protein.

Figure 31. JC-171 binding interactions within binding pocket of the NACHT domain.
Hydrogen bonds were formed with amino acids: Arginine 237, Arginine 351, Glutamine
509, and Isoleucine 521.

3.5 Production of NLRP3 protein
3.5.1 Plasmid Preparation
Given the promising results from the binding interaction, modeling, and
biochemical studies, and also the need to further characterize the ATPase activity, we
decided to engineer human full length NLRP3 proteins, with the expertise of collaborator
Dr. Darrell Peterson, to further support our studies and facilitate the discovery of more
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potent analogs. To accomplish this, a full length human NLRP3 protein with pEGFP-C2
vector for mammalian expression was obtained (Figure 32).13 To facilitate purification
process, a His-tag was introduced to the sequence by the polymerase chain reaction
(PCR) technique with a forward primer containing a sequence encoding a His-tag.

Figure 32. pEGFP-C2 vector with full length human NLRP3 protein insert.
Unfortunately, the attempt with PCR for the full sequence with the primer encoding Histag did not succeed. The sequence was re-examined for possible restriction sites that
could be utilized to synthesize the sequence in parts (Figure 33). Restriction sites are
palindromic sequences that specific restriction enzymes can recognize and cleave.
Cleavage of the double stranded DNA then leaves an over-hang DNA which can then be
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ligated to the complementary sequence from the same restriction site. 164 To determine
which pieces could be synthesized, forward and reverse primers were used to generate
these fragments: NheI/SacI, SacI/BamHI, BamHI/EcoR1, EcoR1/XhoI, NheI/BamHI,
EcoR1/XhoI, BamHI/XhoI, and SacI/EcoR1.
NheI
ggatgctagcatgcaccatcaccatcaccatgcaagcacccgctgcaagctggccagg
ggatgctagcatgcatcaccatcaccatcacaagatggcaagcacccgctgcaagctggccaggtacctggagga
cctacgatcgtacgtagtggtagtggtagtgttctaccgttcgtgggcgacgttcgaccggtccatggacctcct
75
SacI
caagaccaagacgtgtgagagccccgtgagtcccattaagatggagctcctgtttgaccccgatgatgagcattc
gttctggttctgcacactctcggggcactcagggtaattctacctcgaggacaaactggggctactactcgtaag
675
XmaI
ggtgtacgtcttcttcctttccagtttgctgcagccccggggagggagccaggagcacggcctctgcgcccacct
ccacatgcagaagaaggaaaggtcaaacgacgtcggggcccctccctcggtcctcgtgccggagacgcgggtgga
1425
BamHI
aggaaggacgaacgttccaggatcccgtttgaagcttcccagccgagacgtgacagtccttctggaaaactatgg
tccttcctgcttgcaaggtcctagggcaaacttcgaagggtcggctctgcactgtcaggaagaccttttgatacc
1725
BglII
cttggagaagaaattaagttgcaagatctctcagcaaatcaggctggagctgctgaaatggattgaagtgaaagc
gaacctcttctttaattcaacgttctagagagtcgtttagtccgacctcgacgactttacctaacttcactttcg
1875
EcoRI
aattttatgtgaaaaagccaagaatccacagtgtaacctgcagaaactggggttggtgaattctggccttacgtc
ttaaaatacactttttcggttcttaggtgtcacattggacgtctttgaccccaaccacttaagaccggaatgcag
2550
XhoI
agaaaagcctgagctgaccgtcgtctttgagccttcttggtagctcgaggc
tcttttcggactcgactggcagcagaaactcggaagaaccatcgagctccg 29274

Figure 33. The insert sequence with found restriction sites highlighted and labeled.
DNA sequence number is indicated in bold at the end of each segment.
The PCR experiments were performed with 30 cycles for amplification in a
thermocycler. PCR products were visualized by agarose gel electrophoresis, a common
technique to visualize and separate DNA fragments by size. As shown in Figure 34, the
largest piece that was successfully synthesized by PCR was NheI/BamHI with 1,670 base
pairs. The other piece BamHI/XhoI with 1,304 base pairs was successfully identified the
second attempt with PCR (Figure 34). The primers used to synthesize these pieces were
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Figure 34. PCR products run on agarose gel. (Left) PCR products for pieces:
NheI/SacI, SacI/BamHI, BamHI/EcoR1, EcoR1/XhoI, NheI/BamHI, EcoR1/XhoI,
BamHI/XhoI, and SacI/EcoR1. (Right) Second PCR attempt at BamHI/XhoI.
forward primers: NheI/BamHI 5'-ggatgctagcatgcaccatcaccatcaccatgcaagcacccgctgca
agctggccagg-3’

and

BamHI/XhoI

5’-caggatcccgtttgaagcttcccagccgagacgtg-3’.

The

reverse primers to make these pieces were: BamHI/NheI 5’-ggggatcctggaacgttcgtcc
ttccttccttttcctc-3’ and XhoI/BamHI 5’-gcctcgagctaccaagaaggctc aaagacgacgg-3’. The
PCR products for Nhe1/BamHI and BamHI/XhoI were recovered with Qiaquick gel
extraction kit. The expression vector used for NheI/BamHI and BamHI/XhoI was
expression vector pcDNA 3.1/Hygro that has all three necessary restriction sites (Figure
35).165 NheI/BamHI and BamHI/XhoI and their corresponding vectors were ligated
together and transformed into BL21 (DE3) competent E. coli cells. The cloned plasmids
were collected then digested with appropriate enzymes and visualized on agarose gel.
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Figure 35. pcDNA 3.1/Hygro mammailian expression vector with necessary restriction
sites indicated in red circles.
As shown in Figure 36, the clones showed individual inserts. Inserts were then sequenced
(Figure 37).
Purified plasmid with BamHI/XhoI
insert was digested with NheI and BamHI
restriction enzymes. The insert from the
plasmid with NheI/BamHI was then ligated
into vector with BamHI/XhoI insert. The
newly formed plasmid with entire sequence
was then transformed back into competent
bacterial cells. Qiagen mini-preps were
done for 4 bacterial colonies (Qiagen,
Hilden, Germany).
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Figure 36. Cloned pcDNA 3.1/Hygro+
inserts digested with appropriate
enzymes. (Left) Cloned vector +
BamHI/XhoI insert. (Right) Cloned
vector + NheI/BamHI insert.

Figure 37. Cloned pcDNA 3.1/Hygro+ inserts sequenced. (Top sequence) The
sequence from insert NheI/BamHI insert. (Bottom sequence) The sequence from insert
BamHI/XhoI.
Plasmids collected from 4 colonies were digested with 2 different sets of restriction
enzymes, NheI/XhoI or BamHI/XhoI enzymes. Colonies 1-3 had the correct inserts for
NheI/XhoI and BamHI/XhoI. However, colony 4 did not have the correct NheI/XhoI insert
so was discarded (Figure 38). Diluted pooled plasmid was tested for absorption at 280
nm and 260 nm with UV-vis spectrophotometer to estimate the concentration of the
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plasmid and determine how much bacteria was
needed to make enough plasmid for transfection
and determine the purity of the sample.
The UV-vis spectrophotometer reading detected
0.517 AU for 280 nm and 0.914 AU for 260 nm. This
gave a ratio of 1.77 indicating the nucleic acid
content was quite pure. Using the extinction
coefficient

and

Beer-Lambert’s

law

the

concentration of plasmid
was estimate to be 457
ug/ml. From this it was
Figure 38. Colonies 1-4 of
cloned pcDNA 3.1/Hygro+ full
NLRP3 sequence cut with either
NheI and XhoI restriction
enzymes or BamHI and XhoI
restriction enzymes.

determined

how

much

more bacteria needed to
be used to clone enough
plasmid.

Plasmids were again collected and purified with and cut
with restriction enzyme pairs: NheI/XhoI, NheI/BamHI, and
BamHI/XhoI. These digested plasmids were then visualized
on agarose gel (Figure 39). When digested with enzymes
for the full sequence, NheI/XhoI, or enzymes for either
NheI/BamHI and BamHI/XhoI piece, the resulting pieces
analyzed by agarose gel were the correct size. The plasmid
produced was enough for transfection.
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Figure
39.
Purified
colony
of
pcDNA
3.1/Hygro+ full NLRP3
sequence.
Plasmids
were either cut with
either NheI and XhoI
restriction
enzymes,
NheI and BamHI, or
BamHI
and
XhoI
restriction enzymes.

3.5.2 Transfection
Human embryonic kidney 293 cells
(HEK-293) were transfected with plasmid
using

ExpiFectamine

TM

293

kit

(ThermoFisher Scientific, Waltham, MA). As
shown in Figure 40, the optimal time for
protein expression were days 1-3, after which
the expression of NLRP3 protein decreased
due to reduced cell viability. Collectively our
results confirmed that we can successfully
express full length NLRP3 proteins to support

Figure 40. Immunoblot of HEK 293
cells
transfected
with
pcDNA
3.1/Hygro+ full NLRP3 sequence.
NLRP3 visualized with anti-NLRP3 and
secondary antibody anti-rabbit IgG with
conjugated HRP.

our continuning studies.
3.6 LC-MS
3.6.1 Method development
To evaluate the ability of our compound to penetrate the BBB and compare to the
potent NLRP3 inhibitor with comparable therapeutic in vivo MS mouse models, MCC950,
LC-MS was utilized. In order to quantify the concentration of compounds in the brain
samples, first a reliable method had to be established. To help with precision and account
for matrix effects, Glipizide, another sulfonamide small-molecule compound, was chosen
as the internal standard. Glipizide proved stable and flexible in terms of ionization.
Both positive and negative ion modes of ESI were tested for detection of each
compound. However, it was determined that separate ionization modes needed to be
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used for each compound for detection. Negative ionization mode of ESI was used for
MCC950; the reason for the better signal in this mode was that the compound was
purchased as a salt with a negative charge on the nitrogen of the sulfonamide group. JC171 (GA4), however, gave a better signal in positive ion mode due to its amine.
Conveniently, the internal standard Glipizide yielded a significant signal in either positive
or negative mode, so the same internal standard could be used for all samples for both
method validation and dosed mice brain samples.

Figure 41. Retention times and extracted ion intensity for product ions of JC-171
(GA4), MCC950, and Glipizide. Product ions for MCC950 and GA4 used for
quantification are depicted by red peaks.
In multiple reaction monitoring (MRM) the most significant product ions found for
MCC950, with a molecular weight of 404.5 (C20H24N2O5S), were: 204 ([M-200]-) and 80
([M-324]-) m/z. The product ion used for quantification was 204 and the retention time for
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product ions were 3.110 minutes. The product ions monitored for GA4, with a molecular
weight of 385.8 (C16H17ClN2O5S), were: 304 ([M + H-80]+) and 169 ([M + H-215]+) m/z.
The product ion used for quantification was 169 and the retention time for product ions
were 2.590 minutes. For Glipizide, with a molecular weight of 445.5 (C21H27N5O4S), either
product ion 319 ([M – H-126]-) for negative ionization ESI mode or 321([M + H-125]+) for
positive ionization mode was used. For Glipizide product ion, the retention time was 2.520
minutes (Figure 41). The product ion with the highest signal was monitored for
quantification purposes and the other product ion was monitored for quality control.
Additionally, to determine if carry over would occur between samples a double blank
sample, a sample with neither internal standard or analyte, was used. It was determined
that there was minimal carry over between samples (Figure 42).

Figure 42. Multiple reaction monitoring for GA4, MCC950, and Glipizide in double
blank sample to determine carry over.
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3.6.2. Validation
The extraction method had to be adjusted to account for both compounds being
run through different ionization ESI modes. When testing different extraction solvents for
extracting the analytes from brain tissue, it was determined that 1% FA in ACN was most
effective for compound GA4.
121617A.rdb (GA41): "Linear Through Zero" Regression ("No" weighting): y = 0.225 x (r = 0.9991)
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Figure 43. Calibration curve of GA4 from brain tissue at concentrations: 2.5, 25, 125,
250, 500, 1,250 ng/g. Equation (y = 0.225 x (r=0.9991))
The extraction solvent 1%FA in ACN could only be used for both if the solvent was
completely evaporated after filtering through a phospholipid filter plate (Biotage, Uppsala,
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Sweden). Evaporation of solvent removed FA from sample and prevented negative ion
suppression of MCC950. The solvent used for reconstitution also required optimization to
use for both analytes. MCC950 was more flexible in terms of solvent used for
121617A.rdb (MCC950): "Linear Through Zero" Regression ("No" weighting): y = 4.92 x (r = 0.9987)
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Figure 44. Calibration curve of MCC950 from brain tissue at concentrations: 2.5, 25,
125, 250, 500, 1,250 ng/g. Equation ( y = 4.92 x (r=0.9987))

reconstitution and could be done with ACN or methanol. However, without pure methanol
or a 90:10 water/methanol reconstitution solvent, GA4 was retained on the column. For
simplicity methanol was the chosen solvent for reconstitution.
To accurately quantify analyte in brain tissue, a six-point calibration curve for both
compounds (2.50-1,250 ng/g) were run after extraction from brain tissue (Figure 43, 44).
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The calibration curves were reproducible with a coefficient of determination for MCC950
(R2)= (0.9920-0.9998) and for GA4 (R2)= (0.9940-0.9982). Neither linear regression
equation was weighted. The relative residuals remained below 20% for each point on
either calibration curve.
The with-in assay precision and bias were determined for each 3 runs. Each run
had a calibration curve and 3 repeats of low (7.5 ng/g), medium (150 ng/g), and high
(1,000 ng/g) samples. Both the % CV (precision) and % Bias (accuracy) remained below
20% and within allowable error with 2 exceptions (Table 1-3). The with-in %CV for
MCC950 fell in the range of 2.050- 7.100% and the %CV for GA4 fell in the range of
0.5300-6.130%. The % Bias for MCC950 fell in the range of 0-14.90% with the exception
of the low (7.5 ng/g) sample in run 3. The %Bias for GA4 fell in the range of 10.20-18.90%
with the exception of the high (1,000 ng/g) sample in run 3. The MCC950 low QC samples
(7.5 ng/g) ran slightly higher than what was accurate. GA4 high QC samples (1,000 ng/g)
were significantly lower than what the values should have read, indicating human error in
sample preparation so this data was not included in in-between assay %CV and %Bias
calculations.
The in-between precision and accuracy was then calculated from pooled data. The
in-between %CV among low, medium, and high samples from MCC950 ranged between
11-15%. The %Bias for MCC950 fell in the range of 1.000-7.000% (Table 4). For GA4,
the in-between %CV among low, medium, and high samples ranged from 2.000-5.000%.
The %Bias for GA4 fell within 14.00-17.00% (Table 5). All %CV and %Bias fell with-in
allowable error ≤ 20%, demonstrating that the method was sufficient for use in
determining the concentration of these compounds from tissue samples.
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Run 1 QC :
MCC950

Run 1

Sample Name
Test
2.5 ng/g
MCC950 & GA4
25 ng/g MCC950
& GA4
125 ng/g
MCC950 & GA4
250 ng/g
MCC950 & GA4
500 ng/g
MCC950 & GA4
1250 ng/g
MCC950 & GA4

MCC950

GA4

Repeat

High
(1000
ng/g)

253.5

116.5

1

7.550

135.5

1035

4.695

1.015

2

6.500

136.0

1140

22.45

8.300

3

7.150

129.0

1125

119.5

132.0

Mean

7.067

133.5

1100

224.5

287.5

SD

0.4330

3.189

46.37

515.0

520.0

%CV

6.123

2.388

4.215

1720

1235

%Bias

-5.778

-11.00

10.00

Blank

No Peak

No Peak

Double Blank
High QC (1000
ng/g MCC950 &
GA4)
Low QC (7.5
ng/g MCC950 &
GA4)
High QC (1000
ng/g MCC950 &
GA4)
Low QC (7.5
ng/g MCC950 &
GA4)

No Peak

No Peak

High QC (1000
ng/g MCC950 &
GA4)
Low QC (7.5
ng/g MCC950 &
GA4)
Mid QC (150
ng/g MCC950 &
GA4)
Mid QC (150
ng/g MCC950 &
GA4)
Mid QC (150
ng/g MCC950 &
GA4)

Low (7.5 ng/g)

Mid (150
ng/g)

Run 1 QC:
GA4

Low (7.5 ng/g)

Mid (150
ng/g)

High
(1000
ng/g)

1035

1145

Repeat

7.550

8.700

1

8.7

155.5

1145

1140

1175

2

8.7

174.5

1175

6.500

8.700

3

8.6

166.0

1125

1125

1125

Mean

8.667

165.3

1148

7.150

8.600

SD

0.04710

7.771

20.55

135.5

155.5

%CV

0.5440

4.700

1.789

136.0

174.5

%Bias

15.56

10.22

14.83

129.0

r

0.9990

0.9990

r2

0.9980

0.9980

Table 1. Run 1 calibration curve and low, medium, and high QC samples.
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Run 2 QC
: MCC950

Run 2
Sample Name
2.5 ng/g
MCC950 & GA4
25 ng/g MCC950
& GA4
125 ng/g
MCC950 & GA4
250 ng/g
MCC950 & GA4
500 ng/g
MCC950 & GA4
1250 ng/g
MCC950 & GA4
Blank
Double Blank
High QC (1000
ng/g MCC950 &
GA4)
Low QC (7.5
ng/g MCC950 &
GA4)
High QC (1000
ng/g MCC950 &
GA4)
Low QC (7.5
ng/g MCC950 &
GA4)
High QC (1000
ng/g MCC950 &
GA4)
Low QC (7.5
ng/g MCC950 &
GA4)
Mid QC (150
ng/g MCC950 &
GA4)
Mid QC (150
ng/g MCC950 &
GA4)
Mid QC (150
ng/g MCC950 &
GA4)

MCC950

GA4

Repeat

Mid (150
ng/g)

Low (7.5 ng/g)

High
(1000
ng/g)

1.740

0.8700

1

8.000

143.5

1100

21.55

8.200

2

6.900

144.0

1210

112.5

129.5

3

7.600

137.0

1195

182.0

205.0

Mean

7.500

141.5

1168

510.0

475.5

SD

0.4550

3.189

48.70

1260

1270

%CV

6.061

2.253

4.169

0

-5.667

16.83

No Peak

No Peak

No Peak

No Peak

%Bias

1100

1185

Run 2
QC: GA4

8.000

8.950

Repeat

1210

1215

1

8.950

160.5

1185

6.900

8.950

2

8.950

180.0

1215

1195

1165

3

8.850

171.0

1165

7.600

8.850

Mean

8.917

170.5

1188

143.5

160.5

SD

0.04710

7.969

20.55

144.0

180.0

%CV

0.5290

4.674

1.729

18.89

13.67

18.83

137.0

%Bias

r

0.9990

171.0
0.9990

r2

0.9970

0.9980

Mid (150
ng/g)

Low (7.5 ng/g)

Table 2. Run 2 calibration curve and low, medium, and high QC samples.
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High
(1000
ng/g)

Run 3 QC :
MCC950

Run 3
Sample Name
2.5 ng/g
MCC950 & GA4
25 ng/g
MCC950 & GA4
125 ng/g
MCC950 & GA4
250 ng/g
MCC950 & GA4
500 ng/g
MCC950 & GA4
1250 ng/g
MCC950 & GA4
Blank
Double Blank
High QC (1000
ng/g MCC950 &
GA4)
Low QC (7.5
ng/g MCC950 &
GA4)
High QC (1000
ng/g MCC950 &
GA4)
Low QC (7.5
ng/g MCC950 &
GA4)
High QC (1000
ng/g MCC950 &
GA4)
Low QC (7.5
ng/g MCC950 &
GA4)
Mid QC (150
ng/g MCC950 &
GA4)
Mid QC (150
ng/g MCC950 &
GA4)
Mid QC (150
ng/g MCC950 &
GA4)
r
r2

MCC950

GA4

Low (7.5
ng/g)

Repeat

Mid (150 ng/g)

High (1000
ng/g)

3.500

21.20

1

8.920

162.0

862.0

38.40

20.80

2

9.040

172.2

864.0

121.8

88.20

3

10.40

177.2

826.0

258.0

159.6

Mean

9.453

170.5

850.7

490.0

212.0

SD

0.6710

6.325

17.46

1252

1322

%CV

7.100

3.711

2.053

%Bias

26.04

13.64

-14.93

No Peak

4.940

No Peak

No Peak

862.0

218.0

Run 3 QC:
GA4

8.920

7.660

Repeat

864.0

216.0

1

7.660

178.2

218.0

9.040

8.520

2

8.520

179.0

216.0

826.0

212.0

3

8.880

172.0

212.0

10.40

8.880

Mean

8.353

176.4

215.3

162.0

178.2

SD

0.5120

3.128

2.494

172.2

179.0

%CV

6.127

1.773

1.158

%Bias

11.38

17.60

-78.47

177.2
0.9999

172.0
0.9972

0.9998

0.9944

Low (7.5
ng/g)

Mid (150 ng/g)

High (1000
ng/g)

Table 3. Run 2 calibration curve and low, medium, and high QC samples.
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MCC950 QC Total
Run

Repeat

Low (7.5 ng/g )
1
2
3
1
2
3
1
2
3

1

2

3
Mean
SD
%CV
%Bias
Linearity

7.550
6.500
7.150
8.000
6.900
7.600
8.920
9.000
10.40
8.010
1.170
15.00
7.000
2.5ng/g - 1250
ng/g

Mid (150 ng/g)
135.5
136.0
129.0
144.0
144.0
137.0
162.0
172.0
177.2
148.5
16.50
11.00
-1.000
r2

High (1000 ng/g)
1035
1140
1125
1100
1210
1195
862.0
864.0
826.0
1040
142.3
14.00
4.000
0.9920-0.9998

Table 4. In-between precision and bias for low, medium, and high MCC950 samples.

GA4 QC Total
Run

Repeat

Low (7.5 ng/g )

Mid (150 ng/g)

High (1000 ng/g)

1

8.700

155.5

1145

2

8.700

174.5

1175

3

8.600

166.0

1125

1

8.950

161.0

1185

2

8.950

180.0

1215

3

8.850

171.0

1165

1

7.660

178.2

2

9.000

179.0

3

8.880

172.0

8.650

170.7

1168

0.3800

8.060

28.67

%CV

4.000

5.000

2.000

%Bias

15.00

14.000

17.00

1

2

3

Mean
SD

Linearity

2.5ng/g - 1250 ng/g

r2

0.9940-0.9982

Table 5. In-between precision and bias for low, medium, and high GA4 samples.
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3.6.3. Application and Discussion
To determine the BBB penetration of GA4 and compare to the more potent
MCC950, brain samples from mice administered GA4 and MCC950 at 0.1 mg/kg and 0.5
mg/kg via intraperitoneal injection, were collected after 2 h of compound administration.
Following the optimized extraction method and established LC-MS method, the samples
were weighed, homogenized, and extracted. The estimation of concentrations detected
from tissue were calculated based on calibration curves established (Table 6).
On average the concentration of drug extracted from the brain tissue of mice given
intraperitoneal injections of 0.1 mg/kg of MCC950 was 0.7530 ng/g. This value fell outside
the calibration curve for this compound so this value was from extrapolation and the
likelihood of accuracy for this value was lower than interpolated values. However, this
does not change the overall conclusion of these results combined. Comparatively, from
mice given the same dose of GA4, an average of 9.200 ng/g of drug was detected in the
brain tissue.
When mice were injected with 0.5 mg/kg of GA4, the average detected
concentration in the brain tissue was 18.12 ng/g. However, the difference between the 2
samples was high. Given the amount of GA4 detected in mice given 0.1 mg/kg, the higher
value seemed more reasonable. The reason for this difference did not appear to be an
error in extraction or an issue with the method; when the other half of the brain from
mouse #7 and #8 was tested the same distinct difference in concentration of drug
detected was observed. This indicated that the reason for this difference may have been
the sample itself. In mice given the same dose of MCC950, the detected concentration
from the brain tissue was only and average of 3.050 ng/g. So, despite this discrepancy in
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the brain samples of mice injected with GA4, the amount detected was still higher than
the concentration of MCC950 detected from mice given the same dose. GA4 (JC-171),
not only demonstrated BBB penetration but was superior to the BBB penetration of the
more potent NLRP3 inhibitor MCC950. This may partially explain the reason for
comparable therapeutic in vivo activity in mouse model of MS.
Sample # and Drug Dose

MCC905 ng/g

GA4 ng/g

ND
ND
3.240
2.860
0.6460
0.8600
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND
29.00
7.240
10.84
7.560

1-vehicle
2-vehicle
3-MCC950 0.5mg/kg
4-MCC950 0.5mg/kg
5-MCC950 0.1mg/kg
6-MCC950 0.1mg/kg
7-GA4 0.5mg/kg
8-GA4 0.5mg/kg
9-GA4 0.1mg/kg
10-GA4 0.1mg/kg
ND = None Detected

Table 6. Concentration of drug detected from the brain tissue of mice
given the indicated doses of drug by intraperitoneal injection.
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Chapter 4: Methods and Materials
4.1 MST
4.1.1 NLRP3 (LRR), NLRP3 (full length), and NLRP3 (K232A)
The proteins used were either recombinant mouse NLRP3 (LRR) with n-terminal
His-tag (amino acids: 671-1033) (LS Bio, Seattle, WA), recombinant human NLRP3 with
n-terminal His-tag (amino acids: 2-1036) (BPS bioscience, San Diego, CA), or
recombinant mutant human NLRP3 (K232A) with n-terminal His-tag (amino acids: 21036) (BPS bioscience, San Diego, CA). Protein was labeled with His-tag RED-tris-NTA
monolith protein labeling kit according to manufacturer’s instructions (Nanotemper,
München, Germany). The labeling kit has high efficiency and removal of excess dye or
purification is not necessary. Monolith NT. Automated machine was used for MST assay
(Nanotemper, München, Germany). 10ul of the NT-647 labeled protein was added to 12
wells of a 384 well plate (Corning, Corning, NY) at a final concentration of 50 nM with the
addition of 10 µl of 12 different concentrations ligand and a final concentration of 5%
DMSO in each well. MST premium-coated capillary chip was inserted into the 12 wells
and then placed into the MST machine. The MST excitation was set to 40% for sufficient
fluorescence counts and the MST power was set to medium for the best signal to noise
ratio. All binding data used passed MST quality checks such as: no aggregation,
consistent initial fluorescence, and no photo-bleaching.
4.1.2 ASC
The protein used was recombinant human ASC/TMS1 with GST tag (Novus,
Littleton, CO). Protein was labeled with cysteine reactive monolith protein labeling kit red68

maleimide and purified according to manufacturer’s instructions (Nanotemper, München,
Germany). The fractions were run through UV-1800 Shimazdu spectrophotometer the
absorption at wavelengths at 280 and 680nm were compared by using the molar
absorbance of the dye (250,000 M−1cm−1) to calculate degree of labeling and the molar
extinction coefficient of the protein (67123) to calculate the protein concentration in each
fraction (Shimazdu, Kyoto, Japan).

Figure 45. Purified fractions from fluorescently tagged (NT-647) ASC protein.

The best fraction with nearly equal signal from protein and fluorescent tag, fraction 5, was
used in MST experiments (Figure 45). Monolith NT. Automated machine was used for
MST assay (Nanotemper, München, Germany). 10ul of the NT-647 labeled ASC protein
was added to 12 wells of a 384 well plate (Corning, Corning, NY) at a final concentration
of 10nM with the addition of 10 µl of 12 different concentrations ligand and a final
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concentration of 5% DMSO in each well. MST premium-coated capillary chip was inserted
into the 12 wells and then placed into the Monolith NT.Automated MST machine
(Nanotemper, München, Germany). The MST excitation was set to 95% for sufficient
fluorescence counts and the MST power was set to medium for the best signal to noise
ratio.
4.2 ADP-Glo
3 µl of recombinant human NLRP3 aa 2-1036 80117 (BPS Bioscience, San Diego,
CA) was incubated in a 384 well white plate (Greiner Bio-one, Kremsmünster, Austria) at
a concentration of 7ng/ul with 1 µl of the given concentration of compounds mentioned
for 15 min at 37 °C in reaction buffer 20 mM Tris-HCl (pH 7.8), 20 mM MgCl2, 133 mM
NaCl, 3 mM KCl, 0.56 mM EDTA, and 2% DMSO, following the reference protocol.144 250
μM of ultra-pure ATP, provided by ADP-Glo kit (Promega, Madison, WI), was added to
each well and further incubated at 37 °C for 40 minutes. Due to the small quantities added
in each step, protein, compound, and ATP were all added via acoustic liquid handling
technology, Echo 555 (Labcyte, San Jose, CA). Luminescent ADP-Glo Kinase Assay kit
was used to detect and quantify ADP produced by ATP hydrolysis of the ATPase of
NLRP3 per manufacturer’s protocol (Promega, Madison, WI). Clariostar multi-mode
microplate reader was used to quantify luminescence produced from each reaction (BMG
Labtech, Ortenburg, Germany).
4.3 Molecular Modeling
With no crystal structure of NBD domain of NLRP3, homology models were
generated from template crystal structure of NLRC4 (PDB code 4KXF)158. Template 4KXF
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was chosen based on sequence similarity in BLAST search of FASTA sequence of NBD
(aa 220-536) of human NLRP3 (Uniprot code Q96P20). Sequence alignment was done
via EMBOSS needle pairwise sequence alignment (EMBL-EBI, Hinxton, UK).162 100
models were generated using MODELLER v 9.17.157 Models were compared via
Ramachandran plots. The model 70 was chosen based on acceptable Ramachandran
plot and further validation by docking ADP from the crystal structure of NLRC4 back into
the nucleotide binding pocket. Model 70 was minimized using SYBL-X 2.1.1(Tripos
Associates, St. Louis, MO) using Tripos force field and Gasteiger-Hückel charges.
Compounds were docked into a chosen model using GOLD 5.4 (The Cambridge
Crystallographic Data Centre, Cambridge, England). Pictures of protein and docked
ligands were generated using PyMol (Schrödinger, LLC, New York, NY). HINT scores
were calculated to determine if hydropathic interactions were favorable.160
4.4 NLRP3 production
4.4.1 Plasmid and General Procedure
Plasmid pEGFP-C2-NLRP3 ( catalog # 73955) was purchased from nonprofit plasmid
repository addgene.13 Purification of plasmid from bacteria with done with Qiagen miniprep per manufacturer’s protocol (Qiagen, Hilden, Germany). When PCR was attempted
using

forward

primer

with

added

histidine

tag

on

amino

terminus

(5’

ggatgctagcatgcaccatcaccatcaccatgcaagcacccgctgcaagctggccagg 3’) and reverse primer
(5’ cgggatccctaccaagaaggctcaaagacgacggtcag 3’) the correct sequence could not be
produced from PCR. To get correct sequence extra restriction sites had to be used to
divide the sequence to be cloned into 2 parts. Restriction sites used included: NheI at
amino terminus, BamHI in the middle of the sequence, and XhoI at the carboxy terminus.
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Primer’s to introduce sequences and clone protein sequence in 2 parts were purchased
from Invitrogen: NheF (5’ ggatgctagcatgcaccatcaccatcaccatgcaagcacccgctgcaagctggc
cagg 3’), BamR(5’ ggggatcctggaacgttcgtccttccttccttttcctc 3’), BamF (5’ caggatcccgtttgaa
gcttcccagccgagacgtg 3’), and XhoR (5’ gcctcgagctaccaagaaggctcaaagacgacgg 3’)
(Invitrogen, Carlsbad, CA) .
4.4.2 PCR
DreamTaq Green PCR Master mix (2x) (ThermoFisher Scientific, Waltham, MA)
was thawed, vortexed and quickly centrifuged. A PCR tube was cooled down on ice and
to it was added: 25 µl of DreamTaq Green PCR Master mix, 0.5µM of each forward
primer, 0.5 µM of each reverse primers and 0.5 µg of the template DNA, and enough
nuclease-free DI water to bring the total volume up to 50 µl. Sample was vortexed and
spun down. A thermocycler was then used for 2 minutes at 95°C for initial denaturing of
DNA. After initial denaturing, 30 cycles of denaturation at 95°C for 30 seconds, annealing
at 72°C for 30 seconds, then extension at 72°C for 1 minute. For the final extension, 1
cycle was done at 72°C for 10 minutes (ThermoFisher Scientific, Waltham, MA). 10 uL of
PCR mixture was directly added to gel to analyze via agarose gel electrophoresis
according to protocol (Agarose Gel Electrophoresis protocol, Addgene, Cambridge, MA).
PCR products were recovered using Qiaquick gel extraction kit following the
manufacturer’s protocol (Qiagen, Hilden, Germany). PCR products were sent to Eurofins
Scientific were utilized to determine the sequence (Eurofins Scientific, Brussels, Belgium).
4.4.3 Transformation
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Purified PCR products and vector pcDNA 3.1/Hygro were then digested with the
appropriate enzymes and each piece separately ligated into vector with DNA ligase
according to manufacturer’s protocol (DNA ligation kit, ThermoFisher Scientific, Waltham,
MA). BL21 (DE3) competent E. coli cells were thawed on ice for 10 minutes. 5 uL of 5 ng
of plasmid was added to thawed bacteria cells and mixed by gently tapping. Vials were
left to incubate on ice for 30 minutes. Vials of bacteria and plasmid were heat shocked by
placing vial into a 42°C water bath for 30 seconds. Vial was then placed on ice. 250 uL of
pre-warmed SOC medium was then added to vial. Vial was set to incubate at 37°C on
cell shaker for 1 hour at 225 rpm (ThermoFisher Scientific, Waltham, MA). 50 uL was
plated on pre-warmed plate at 37°C, LB agar selection plates containing 100 ug/ml of
ampicillin, and the rest in the other plate. Plates were inverted and incubated at 37°C
overnight. Qiagen mini-prep was used to collect plasmid from the bacteria (Qiagen,
Hilden, Germany).
4.4.4 Transfection
6 x 107 HEK293 cells were seeded into 30mL of Expi293TM expression medium
and incubated at 37 °C in a humidified environment with 8% CO2 with cell shaker set to
125 rpm (ThermoFisher Scientific, Waltham, MA). A 100 µl aliquot of the cell solution was
added to 0.4% solution of trypan blue dye in PBS at a 1:1 ratio. This trypan blue/cell
solution was then loaded onto a hemocytometer to determine cell density and viability.
Once the cells reached a density between 3-5 x 106 /mL cell density and were still above
95% viability the cells were ready for transfection. 7.5 x 107 cell were then diluted with
25.5 mL of Expi293TM expression medium in a 125 mL flask. 30 µg of purified plasmid
was then suspended in 1.5 mL of Opti-MEM reduced serum medium and gently mixed.
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81 µl of ExpiFectamine TM 293 reagent was then diluted in Opti-MEM I medium to final
volume of 1.5 mL, this was then mixed gently and incubated at room temperature for 5
minutes. The plasmid and ExpiFectamine TM reagent were then mixed together and left to
incubate at room temperature for 20 minutes. The plasmid/ ExpiFectamine TM mix was
then carefully added to the flask of cells in a dropwise manner. The cells were then left to
incubate for 20 hours at 37 °C in a humidified environment with 8% CO2 with cell shaker
set to 125 rpm. After 20 hours, 150 µl of ExpiFectamineTM transfection enhancer 1 and
1.5 mL of enhancer 2 were added to the flask of cell solution (Transfecting Expi293FTM
Cells protocol, ThermoFisher Scientific, Waltham, MA). Since the best time for protein
expression depends of the protein, 2 1 mL fractions of the cell solution were collected
every day for 4 days. 1 of the 1mL fractions from each day was spun down at 10,000 g
for 10 minutes and supernatant removed. Pellets were frozen at -20 °C for 20 minutes.
Cells were lysed with NP-40 RIPA lysis buffer and protease inhibitor. Protein
concentration was calculated via the Bradford assay.
4.4.5 SDS-PAGE
HEK 293 cells were lysed with buffer cooled down to 0 °C containing: 150 mM
NaCl, 1% NP-40, 50 mM Tris (pH 8) and SIGMAFASTTM protease inhibitor cocktail
(Sigma-Aldrich, St. Louis, MO). 350 µl of lysis buffer was added to each aliquot of ~5
million cells for each of the 4 days cells were collected. Mixture was left on ice for 15
minutes. Mixture was then sonicated for 5 seconds and left on ice for 15 minutes. Cell
lysates were then centrifuged at 15,000 rpm at 4°C for 20 minutes. The Bradford assay
was then employed to estimate protein concentration of cell lysates. Sample buffer was
made with 50 µl of 2-Mercaptoethanol and 950 µl of 2x Laemmli Sample buffer (BIO74

RAD, Hercules, CA). 15 µl of cell lysates were then diluted with 15 µl of sample buffer
and boiled at 90°C for 10 minutes in a water bath and then placed on ice. Cell lysates
were spun down at 4°C at 2,350 rpm for 3 minutes. Diluted sample was injected into
CriterionTM 4-15% Tris-HCl 18 well Precast gel (BIO-RAD, Hercules, CA). Gel was run
with BIO-RAD CriterionTM Cell electrophoresis set to 100 V for 2 hours(BIO-RAD,
Hercules, CA).
4.4.6 Immunoblot
Immun-Blot PVDF membrane was soaked in methanol (BIO-RAD, Hercules, CA).
CriterionTM blotter pads were then soaked in Tris/Glycine transfer buffer. Protein was
transferred to membrane with CriterionTM blotter set to 0.4 A for 2 hours. Blot was then
submerged in blocking solution (5% nonfat dry milk, and 50 mL TBST solution) for 1
hour. Anti-NLRP3 antibody was thawed to room temperature. 1 mg/mL of antibody was
diluted 1:800 in 5% nonfat dry milk TBST solution. Blot was washed with TBST solution
(Tris buffered saline with 0.1% Tween-20 (Sigma-Aldrich, St. Louis, MO)) 3 times.
Secondary antibody, anti-rabbit IgG HRP-linked antibody, was thawed and diluted
1:1000 in 5% nonfat dry milk TBST solution and applied to membrane and incubated at
4°C overnight. Blot was washed with TBST solution 3 times and chemiluminescent
substrate solution was added to the blot and labeled protein visualized with GE gel
imager (Amersham, Little Chalfont, UK).
4.5 LC-MS
4.5.1 Materials
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The plasma purchased for method validation was C57BL/6 mouse K2EDTA plasma
(BioreclamationIVT, Westbury, NY). Brains from C57BL/6 mice dosed with known
concentrations of compound by intraperitoneal injection were obtained from collaborators
(Dr. Xiang-Yang Wang Lab). The brain tissue used for controls and calibration curve. To
remove protein and phospholipids after extraction ISOLUTE PPT+ 96 well filter plate was
used (Biotage, Uppsala, Sweden). LC-MS samples were run using a Shimadzu LC-30AD
pump, Shimadzu SIL-30AC autosampler (Shimadzu, Kyoto, Japan), with an AB SCIEX
linear ion trap quadrupole 6500+ (SCIEX, Framingham, MA). The column used to achieve
separation was a Xterra MS C18 3.5 um 2.1x100mm (Waters, Manchester, UK).
4.5.2 Brain extraction
½ of brain from mice dosed with drug or control mice was homogenized in PBS at
a ratio of 1.5mL of PBS per 0.5g of brain. 500uL of brain homogenate from each sample
was spiked with 150ul of 50ng/ml of Glipizide in methanol. Samples were then extracted
with 500ul of ACN with 1% FA and vortexed then left to sit on ice for 15 min. Samples
were then centrifuged at highest rpm for 10 min at 4°C. Supernatant was collected and
then samples were extracted a second time with 500ul of ACN with 1% FA and the same
protocol. Supernatant was combined and then filtered through phospholipid/protein filter
plate, solvent evaporated and then reconstituted with 150ul of methanol and injected onto
LC-MS.
4.5.3 LC-MS Calibration and QC
Standard concentrations and QC samples of each compound were prepared in
PBS and then added to blank mouse plasma or blank mouse brain tissue for the correct
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concentration of ng of drug to g of brain or plasma. The samples were homogenized and
then spiked with 150ul of 50ng/ml Glipizide internal standard and extracted with 1000uL
of ACN with 1% FA and left to sit on ice for 15 min. Samples were centrifuged at highest
rpm for 10min at 4°C, and then supernatant was filtered through phospholipid/protein
filter. Filtrate was evaporated and then reconstituted with 150ul of methanol and then ran
through LC-MS. The final calibration standard concentrations were: 1,250, 500, 250, 125,
25, 2.5 ng/g. The final QC drug concentrations were 7.5, 150 and 1000 ng/g.
4.5.4 LC-MS Parameters
JC-171 samples were run in positive ion mode and MCC950 was run in negative.
Mobile phase A consisted of water with 10mM ammonium acetate and mobile phase B
was methanol. Injection volume was 2uL with a flow rate of 300 uL/min. The optimized
LC-MS parameters for GA4 and internal standard Glipizide were set to: ionspray voltage
(IS) +4500 V, temperature 500 °C, nebulizer gas (GS1) 60, TurboIonSpray gas (GS2) 50,
collision-activated dissociation (CAD) gas medium, declustering potential (DP) +60 V,
and entrance potential (EP) +10 V. Collision cell exit potential (CXP) settings for GA4 was
10.5 eV.

The

MRM

(Multiple

Reaction

Monitoring)

transitions

for

GA4

were m/z 385 → 304 with CE of 21 eV and 385 → 169 with collision energy (CE) of 32
eV. For Glipizide, the MRM was m/z 446 → 321 with CE of 20 eV. Dwell times for both
GA4 and Glipizide were 100 milliseconds.
The optimized LC-MS parameters for MCC950 and internal standard
Glipizide were set to: ionspray voltage (IS) -4500 V, temperature 500 °C, nebulizer gas
(GS1) 60, TurboIonSpray gas (GS2) 50, collision-activated dissociation (CAD) gas
medium, declustering potential (DP) -60 V, and entrance potential (EP) -10 V. Collision
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cell exit potential (CXP) settings for MCC950 was -18.5 eV. The MRM (Multiple Reaction
Monitoring) transitions for MCC950 were m/z 403.5 → 80 with CE of -45 eV and
403.5 → 204 with collision energy (CE) of -30 eV. For Glipizide, the MRM was
m/z 445 → 319 with CE of -20 eV. Dwell times for both MCC950 and Glipizide were 100
milliseconds.
4.5.5 LC-MS Analysis
MRM data acquisition, chromatographic peak integration, data regression using
peak area ratios of the analyte to internal standard, and chromatographic review were
performed using Sciex Analyst, version 1.6.3 software. Linear regression of calibration
curve for MCC950 had an r2 of 0.992-0.9998 and 0.994-0.9982 for GA4. The unweighted
linear regression equation calculated from the calibration curve of each compound was
used to predict the concentration of analyte in each brain sample. The CV was calculated
in excel by dividing the SD by the mean.
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Conclusion
To conclude, our studies demonstrated direct binding of JC-171 to the NLRP3
protein. The binding affinity of JC-171 to the NLRP3 protein was not significantly altered
in mutant NLRP3 (K232A). Additionally, ATPase studies indicated that JC-171 and its
analogs did not interfere with the ATPase activity of NLRP3. This data supports the notion
that JC-171 may bind to the NACHT domain of NLRP3 in a site that is distinct from the
ATP binding site. Molecular modeling studies of JC-171 to the homology model of the
NACHT domain of the NLRP3 protein indicated a possible binding site for JC-171 and
analogs next to the ATP binding pocket, further supporting the assertion that JC-171
binds to the NACHT domain. LC-MS analysis of brain tissue in mice dosed with MCC950
and JC-171 confirmed that JC-171 not only penetrates the BBB but demonstrated better
BBB penetration when compared to MCC950. This data, as well as the binding data
suggesting an alternative MOA, might aid in the explanation of JC-171s comparable
efficacy in ameliorating the progression of disease pathology in EAE, mouse model of
MS, with MCC950, a compound with significantly higher inhibitory potency in vitro.
Together, these results strongly support that our compounds inhibit the NLRP3
inflammasome by directly interacting with the NLRP3 protein, a novel MOA when
compared to other known inhibitors of the NLRP3 inflammasome. These results strongly
encourage further development of such inhibitors as potential therapeutics for
neurodegenerative diseases.
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